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INTRODUCTION 
 
Sjøgren syndrome (SS) is a chronic autoimmune disease of unknown etiology, 
that affects exocrine glands, mainly salivary and lacrimal with marked mononuclear cell 
infiltrate leading to progressive impairment of gland function(1)(2). It commonly 
presents as xerostomia and xerophthalmia. 
According to American- European Consensus Group (AECG), the prevalence of 
primary Sjogren‘s syndrome (pSS) is about 0.2%.  It mainly affects women, with male to 
female ratio of 1:9 (3).The peak incidence is seen in fourth to fifth decade. The 
pathogenesis is multifactorial including environmental, viral and genetic association with 
HLA DR haplotype.  
Systematic multidisciplinary approach is required in proper evaluation of 
Sjogren‘s syndrome, which includes assessment of the oral, ocular and systemic 
components of the disease. Numerous criteria have been proposed till now to facilitate 
the diagnosis of SS and no consensus has yet been reached, even though the need for a 
definitive set of diagnostic criteria is widely recognized. 
Its diagnosis is with help of clinical signs and symptoms of dry mouth and dry 
eyes along with positive test for antibodies to anti-SS-A and anti- SS-B antigen or 
positive salivary gland biopsy, which characteristically shows focal lymphocytic 
infiltration. Labial biopsy which form major diagnostic tool is a painful procedure with 
small but significant proportion of unreliable results. 
Ocular surface is considered as an integrated unit and any dysfunction results in 
scarce or unstablity of the preocular tear film. Various criteria have been proposed to 
diagnose SS, but none has reached a general consensus. Modified AECG (American 
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European Consensus Group) criteria(4) includes dry eye tests like Schirmer I test and 
vital dye staining (Rose Bengal, fluorescein)(5). The ocular staining score (OSS) which 
uses lissamine green dye to grade the conjunctiva and fluorescein dye to grade the cornea 
is included in ACR (American college of Rheumatology association) classification 
criteria(6). Lissamine stain causes less ocular irritation than Rose Bengal(7).  
In our study subjective symptoms of patients suspected of pSS will be assessed 
by validated of OSDI (Ocular Surface Disease Index) questionnaire(8)(9). The purpose 
of this study is to evaluate the diagnostic performance of Schirmer I test, TBUT and OSS 
test in pSS patients by assessing the sensitivity, specificity and likelihood ratio of each 
test performed. This study also aims to correlate between ocular symptoms, signs, 
immunological variables and labial salivary gland biopsy. Schirmer I of 5mm or less 
in 5 mins, TBUT of less than 10 secs and OSS score of 3 or above will be considered as 
abnormal. 
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AIMS AND OBJECTIVE 
 
 
1. To evaluate the diagnostic performance of Schirmer I test, Tear film break-up 
time (TBUT) and Ocular staining score (OSS) test in Primary Sjogren‘s 
syndrome patients in an Indian setting. 
 
2. To analyze the correlation between ocular symptoms, signs, immunological 
variables and labial salivary gland biopsy. 
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MATERIALS AND METHODS 
Study design: Cross sectional, observational study 
Study settings: Department of Ophthalmology, Christian Medical College, Vellore 
Study population: 
This study was conducted over a period of 7 months (February 2014 – August 
2014) in Department of Ophthalmology, Christian Medical College, Vellore. Patients 
diagnosed of Primary Sjogren‘s syndrome or clinically suspected of Primary Sjogren‘s 
syndrome (pSS) with their pathology and immunology reports awaited for confirmatory 
diagnosis as per ACR criteria, were referred from Rheumatology outpatient clinic to 
Department of Ophthalmology. All patients with established diagnosis of pSS who 
satisfied the inclusion criteria were included in the study.  
Inclusion Criteria: 
 Patients diagnosed as Primary Sjogren‘s syndrome (pSS) with age above 18 
years. 
 Patient who are willing to participate in the study and sign the informed consent. 
 
Exclusion Criteria: 
 Patient in whom diagnosis of primary Sjogren‘s syndrome (pSS) has been 
excluded. 
 Patient with other connective tissue disorders. 
 Past head and neck radiation treatment. 
 Current treatment with daily eye drops for glaucoma. 
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 Corneal surgery in last 5 years to correct vision. 
 Cosmetic eyelid surgery in last 5 years. 
 Contact lens wearer 
 Physical or mental condition interfering with successful participation in the study. 
 Pregnancy  
Informed consent 
Informed consent was obtained from all patients included in the study. The 
consent form attached as Appendix 2. Institutional Research Board (IRB) approval was 
obtained from the institution for the conduct of the study (IRB Min .No. 8671 dated 
19.2.14) 
Methods 
All patients diagnosed of Primary Sjogren‘s syndrome or clinically suspected of 
Primary Sjogren‘s syndrome (pSS) with their pathology and immunology reports 
awaited for confirmatory diagnosis as per ACR criteria, were referred from 
Rheumatology outpatient clinic to Department of Ophthalmology 
All patients were asked to stop artificial tear eye drops for 1 day prior to 
ophthalmology examination. Patient presenting to Schell Eye Hospital were recruited, 
explained about the nature and intent of the study and informed consent were taken. 
Patient were asked to fill a validated questionnaire (Ocular surface disease index) 
OSDI including 12 questions, related to their subjective symptom felt the week before. 
Total score was noted. Schirmer I was done by using sterile Schirmer strips without 
anaesthesia and amount of wetting after 5min was noted in each eye tested.
 10 
 
 Fluorescein dye was instilled to determine TBUT and time between last blink and 
the first appearance of randomly appearing dry spot was noted for each eye. Grading of 
the corneal flourescein staining pattern (Step 1 of Ocular SICCA grading) was done.                                     
Anterior segment evaluation was conducted with slit lamp bio microscope. 
Grading of conjunctival lissamine green staining pattern (Step 2 of Ocular SICCA) was 
done. Total OSS for each eye was calculated after summation of corneal fluorescein 
score and conjunctival lissamine green score for the nasal and temporal bulbar 
conjunctiva.  
Schirmer I Test (without anaesthesia):  
It was done before any drops are instilled in the eye. By using sterile Schirmer 
strip (ContaCare Ophthalmic) bent at the notch and placed carefully at the junction of 
outer and middle one-third of inferior fornix of both eyes. Patient was instructed to keep 
both eyes open. Wetting of strip was measured in millimeter after 5mins. A value of less 
than 5mm was considered as abnormal. 
Tear break-up time (TBUT): 
It was done after 2 minutes of placing fluorescein dye strip moistened with a drop 
of saline in inferior fornix. With 10x magnification, high illumination and using cobalt 
blue filter over the light source. The patient was asked to blink and then keep his/her 
eyes open.  
The TBUT, defined as the time in seconds between patient‘s last blink and first 
appearance of random dry spot on the corneal surface, is measured 3 times and mean 
value was recorded. TBUT of less than 10 seconds was considered as abnormal. 
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Corneal Fluorescein Staining Pattern (Step 1 of ocular SICCA grading): 
Each cornea was examined at slit lamp by using cobalt blue filter. It was a time 
sensitive and dynamic process therefore to ensure reproducibility grading was initiated 
between 4-8 minutes following instillation of fluorescein.  
PEEs that stain cornea are counted and scored  
Grading was done as below: 
No PEEs means score 0 
1-5 PEEs means score 1 
6-30 PEEs means score 2 
>30 PEEs means score 3 
Additional point were added if 
1. PEE occurred in the central part of 4mm diameter portion of the cornea. 
2. 1 or more filaments are seen anywhere on the surface of the cornea. 
3. 1 or more patches of confluent staining, including linear staining pattern are 
found anywhere on the cornea. 
The total fluorescein score for the cornea was noted in OSS 1. (Maximum score-6) 
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External eye examination at Slit Lamp:  
            It was performed before application of lissamine green. The slit amp with same 
magnification but decreased illumination using a neutral density filter abnormalities of 
lids, conjunctiva and cornea were noted. 
Conjunctival lissamine green staining pattern (step 2 of the ocular SICCA grading): 
Lissamine green strip moistened with a drop of saline was applied to the inferior 
conjunctival fornix of each eye. Make the patient blink several times to prevent dye from 
pooling in the conjunctival folds. The conjunctiva was examined immediately with the 
slit lamp using 10x magnification and neutral density filter. Grading 
0-9 dots of staining with lissamine in the interpalpebral bulbar conjunctiva –> score 0  
10-32 dots –> score 1 
33-100 dots –> score 2 
>100 dots –> score 3  
Because of difficulty in counting individual dots in the moving eye on the slit lamp, any 
area of confluent staining of more than 4mm sq or more is considered to be more than 
100 dots.  
Nasal and temporal areas of the conjunctiva were graded separately. (OSS 2) 
Maximum score will be 3 for each area. Total maximum score of 6 for each eye. 
The total OSS for each eye was summation of corneal and conjunctival staining. 
Therefore, the maximum possible score for each eye was 12. The eyes were graded 
separately and recorded. OSS score more than 3 was considered as abnormal.  
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Detailed diagrammatic Algorithm of the study  
 
Patients diagnosed of Primary Sjogren‘s syndrome or clinically 
suspected of Primary Sjogren‘s syndrome (pSS) with their pathology 
and immunology reports awaited for confirmatory diagnosis as per ACR 
criteria, were referred from Rheumatology outpatient clinic to 
Department of Ophthalmology 
 
                                                     
 
All patients were asked to stop artificial tear eye drops for 1 day prior to 
ophthalmology examination 
 
                                                                     
          
Patient presenting to Schell Eye Hospital were recruited, explained 
about the nature and intent of the study and informed consent was taken. 
 
                                           
                         
        
Patients were asked to fill a validated questionnaire (Ocular surface 
disease index- OSDI) including 12 questions, related to their subjective 
symptom felt the week before.  Total score was noted 
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Schirmer‘s test I was done by using sterile Schirmer strips without 
anaesthesia and amount of wetting after 5min were noted in each eye 
tested. 
 
              
Fluorescein dye was instilled to determine TBUT and time between last 
blink and the first appearance of randomly appearing dry spot was noted 
for each eye. 
Grading of the corneal flourescein staining pattern (Step 1 of Ocular 
SICCA grading) 
                                                                   
                                 
Anterior segment evaluation was done with slit lamp bio microscope 
                                                                  
              
Grading of conjunctival lissamine green staining pattern (Step 2 of 
Ocular SICCA) was done. Total OSS for each eye were calculated after 
summation of corneal fluorescein score and conjunctival lissamine green 
score for the nasal and temporal bulbar conjunctiva             
                                                                   
 
Result of the test were analysed and correlated with labial biopsy report 
and immunological variables. Data was evaluated for diagnostic 
performance of each test with appropriate statistical analysis  
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  Statistical method used: 
Formula:  
where,  P = sensitivity of test = 72%  
                                       Q = 100 – P  
             d = precision = 10%          
               = 95% confidence interval  
           77 subjects with Sjogren's syndrome and 77 normals with 
           10% precision and 95% confidence limits  
 
Analysis:  
All the data contained in the proforma were entered into an epidata format. For 
non parametric data the descriptive statistic applied were analysed by Interquartile range 
(IQR), that is by analysis of median and 25-75 percentiles. Data were statistically 
evaluated by applying the Statistical Package for the Social Science (SPSS) for windows 
17.0 for the independent sample t-test, Mann-Whitney U-test for comparison of 
Schirmer‘s I test, Tear-breakup time (TBUT), OSS (ocular surface staining) in Primary 
Sjogren‘s syndrome (pSS) and Non Sjogren syndrome group(Non SS). Significant 
results values for less than 0.05 were considered as statistically significant. Patients were 
grouped as follows after analysis: 
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SS group: Patients diagnosed of Primary Sjogren‘s syndrome as per ACR criteria 
Non SS group: Patients clinically suspected of Primary Sjogren‘s syndrome, but 
who did not fulfill ACR criteria. 
The prevalence of pSS (the proportion of the patients who have disease in the 
population under testing) was calculated by using population included in our study as a 
reference. Each of dry eye test performed were analysed for sensitivity (the percentage of 
those symptomatic patients who are positive for the test, a high sensitivity means that a 
negative test can rule out the disease) and specificity (the percentage of normal subjects 
who were test negative, a large specificity means that a positive test can rule in the 
disease). Specificity and sensitivity were calculated comparing pSS and Non SS patients. 
All data were processed in order to calculate Receiver-Operating characteristics curves 
(ROC). This curve will give the diagnostic exactness of a particular test variable by 
plotting the sensitivity of test against the specificity at all possible thresholds.  
 
Assessment of Cutoff Values with the ROC Procedure 
According to the ROC procedure, optimal cutoff value is usually chosen as the 
hinge point of the curve between sensitivity and specificity for each of the observed 
values in the study population. 
In the description of box plot summary of the medium ± SD of the values resulted 
from the study, collected from each group of patients. Data shown in separate figures 
corresponds to the range min-max values (bounded with lines), results values ranging 
from 25% to 75% and median is shown as black lines, from each group of patients. 
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We also calculated the likelihood ratio, a measure that combines information 
about sensitivity and specificity, and gives a direct valuation of how much a positive or 
negative result can change the likelihood that a patient would have the disease, to 
summarize data about diagnostic tests. Positive likelihood ratio (LR+) suggests the 
increase chances of having a disease if the test is positive and is given by sensitivity 
divided by 1- specificity.  
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REVIEW OF LITERATURE 
Sjøgren syndrome (SS) is a chronic autoimmune disease of unknown etiology, 
which affects exocrine glands, mainly salivary and lacrimal with marked mononuclear 
cell infiltrate leading to progressive impairment of gland function(1)(2). It is named after 
a Swedish ophthalmologist Sir Henrik Sjogren (1899-1986) who described it first. It 
commonly presents as xerostomia and xerophthalmia.It can either present alone as 
primary Sjogren's syndrome (pSS) or as secondary Sjogren's syndrome (sSS) when 
associated with an other underlying connective tissue disorder like Rheumatoid arthritis 
(RA) or systemic lupus erythematosus (SLE). 
 
Prevalence: 
Out of the two to four  million persons in  United States having 
 
SS, one  million 
have an established diagnosis (10). The disease remains
 
undiagnosed in most of the cases 
because of the nonspecific nature and heterogeneity of
 
its clinical manifestations. 
According to AECG, the prevalence of primary Sjogren‘s syndrome (pSS) is 
approximately 0.2%.  It mainly affects women, with male to female ratio of 1:9 (3). This 
can be due to effect of sex hormones. Oestrogen has immune stimulating role whereas 
androgens acts as immune suppressor. It can present in any age group but the peak 
incidence is seen in fourth to fifth decade of life. Approximately 60% of SS patients have 
disease
 
secondary to an underlying accompanying with autoimmune disorder such as 
rheumatoid
 
arthritis (RA), systemic sclerosis or systemic lupus erythematosus (SLE). In 
some studies from Rheumatology clinics, it is shown that about 25% of the patients with 
SLE or RA have the histologic evidence of the SS(11) . 
 
 20 
 
In India Primary Sjogren‘s syndrome is rarely reported as studied by Misra et al 
(12)in tertiary care rheumatology clinic even though the clinical and immunological 
profiles were similar to those seen in Western countries. 
 
Genetics:  
Familial clustering of various autoimmune diseases and the co-association of 
other autoimmune diseases in individuals has been frequently reported. Relatives of SS 
patient are commonly found to have other autoimmune diseases (30%)(13). The 
polymorphicity of gene like major histocompatibility complex (MHC) are one of the 
major genetic risk factors for development of autoimmune diseases(14). In SS, 
DRB1*0301-DQB1*0201-DQA1*0501 haplotypes are the major risk factors for  
formation of an anti-SSA/SSB response and to the development of the disease. The 
protective factors were DQA1*02:01, DQA1*03:01 and DQB1*05:01 alleles(15).  
 
Pathogenesis: 
The pathogenesis is multifactorial including environmental, viral and genetic 
association with HLA DR haplotype.  
The chronic immune system stimulation play a central role in pathogenesis as 
demonstrated by several indices of immunological hyper-activity, including various 
autoantibodies, like anti-Ro/SS-A (anti-Ro) and anti-La/SS-B (anti-La). The exact 
mechanism of   the underlying humoral and cellular
 
autoimmune reactions is unknown.
  
Both T and B lymphocytes play a role in its pathogenesis. Increased activity of B cell
 
is 
depicted as hypergammaglobulinemia and the circulating
 
auto antibodies. Organ specific 
auto antibodies are produced against the cellular antigens seen in the salivary ducts, 
nerve cells, thyroid gland, erythrocytes, gastric mucosa, pancreas and the prostate. In 
approximately 60% of the patients with SS non organ specific auto antibodies are seen. 
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These auto antibodies include antibodies
 
to the small RNA protein complexes, which 
include SS-A and SS-B, rheumatoid factor and antinuclear antibodies. These
 
auto 
antibodies contribute to tissue dysfunction before the inflammation
 
is evident(16).  
The histopathological picture of Sjogren‘s syndrome reflects periductal 
sialoadenitis characterized by focal lymphocytic aggregate around the glandular ducts 
including the salivary glands, lacrimal glands and exocrine glands of the respiratory
 
and 
the gastrointestinal tracts and the vagina. Infiltrate consists of T cells, B cells and the 
plasma cells, with predominant activated
 
CD4
+
 helper T cells. T cells produces 
interleukin (IL)-2, 4, 6, 1, and the tumor necrosis factor (TNF) (17). This suggests that 
there is immune mediated destruction of the exocrine glands in patients with pSS.  
Nearly 20% of the infiltrates consists of B cells. These
 
locally produce 
immunoglobulins. These immunoglobulin have auto antibody reactivity(18). Ultimately, 
these infiltrate will extend to occupy entire acinar epithelium, leading to dysfunction of 
glands and manifesting as dry eye and dry mouth and major salivary gland 
enlargement(19).  
‗Benign lymphoepithelial lesions‘ are defined as absence of clinical and 
serological features of SS, with association of some morphological alteration such as 
‗epimyoepithelial sialoadenitis‘. 
The infiltrate in the acinar epithelium,
 
leads to abnormal function of the glands 
which presents as sicca features  and enlarged  major salivary gland(19). The 
inflammatory processes of pSS occur mainly through glandular
 
epithelial cells. These 
cells presents antigen presenting proteins. These cells can
 
promote adhesion, and co-
stimulate T lymphocytes. Antigen-presenting
 
function of epithelial cells is increased by 
cytokines like interferon IFN -γ and TNF-α may help in the function of antigen 
presentation of epithelial cell. IFN-γ induces apoptosis of the salivary gland epithelial 
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cells (SGECs). This is by
 
increased-regulation of the Fas protein. Fas protein is a cell 
surface receptor.  Its activation leads to apoptosis(20), a programmed cell death. The 
expression of the CD40 protein is high in cells of patients
 
with SS than in normal control 
group. CD40 can also be induced in SGECs by IFN-γ and IL-1B(21). SGECs have 
important  role in induction and the maintenance of the lymphocytic infiltrates in  
patients with SS(10). 
According to a study(22), the sera of SS patients have the impaired capacity to 
degrade secondary necrotic cell remnants (SNEC) and deficiency of endonuclease DNase 
1 activity. Their study concluded that after cell necrosis, immune system of SS patients 
may be extremely exposed to necrotic debris and play a major role in autoimmune and 
inflammatory reactions seen in this disease.  
Apart from anti SSA and anti SSB, the newer antibody, anti-salivary gland 
protein (SP1) has been identified in Sjogren‘s syndrome patients(23). 
 
Autoimmune antibodies: 
 
Anti SS-A and Anti SS-B antibodies 
Auto antibodies in the pSS are mainly against the Sjogrens autoantigens SS-A 
and SS-B and against IgG rheumatoid factor. The SS-A and SS-B autoantigens consist of 
many antigenic proteins which are coupled to small RNA molecules. These RNA-protein 
molecules are seen in all human cells. These autoantibodies can be detected using 
counter-immunoelectrophoresis, immunoblotting technique, ELISA or RNA 
precipitation assays. Counter-immunoelectrophoresis is mainly used for anti SSA 
antibodies and immunoblotting technique is used for anti SSB. 60-70 percentage of 
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patients with SS have anti SSA but they are not specific indicator of the disease. 40-50 
percentage of patients with pSS have anti SSB which are more specific than anti SSA. 
The auto antibodies may be the product of an oligoclonal B-cell proliferation and its 
pathogenic role and origin in pSS is still controversial. 
In patients with the multisystem autoimmune disease like pSS auto antibodies are 
classified into 2 major groups; auto antibodies to DNA and non DNA antigens. The non 
DNA antigens include antinuclear antibodies to the extractable or soluble nuclear 
antigens (which has small ribonucleic acid that is (RNA) connected to non histone 
proteins). Three main categories includes: the U group including U1–U6 small nuclear 
RNAs, the Ro group and the La group.  
The Ro/SSA antigen consist of a 60kDa protein and has small nucleocytoplasmic 
RNA protein complex (hY1, hY3, hY4, hY5)(24). The La/SSB antigen acts as 
termination factor for RNA formation and is of 48kDa protein(25).  
The finding of serum antibodies which are directed against the muscarinic M3 
receptor gives advance understanding in the pathogenesis of not only  glandular 
dysfunction but also related features of autonomic dysfunction in some patients(26). 
The presence of Ro or SSA and La or SSB auto antibodies in serum is suggestive 
of early onset , longer disease duration and  extra glandular disease manifestations like 
splenomegaly or lymphadenopathy, vasculitis, purpura, lymphocytic infiltration of the 
labial salivary glands and recurrent parotid gland enlargement(27)(28)(29)(30).  
Pourmand et al(31)
 
had reported a poor correlation between the serum titres of 
IgA antibodies and SS-A and SS-B antigens and the oral and ocular sicca symptoms. 
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Hammi et al (32)
 
conducted a study on 40 patients and 20 healthy controls who 
met the 1993 criteria ofEuropean community and who were age and sex matched with no 
sign or symptom of the disease. The sample of their serum as well as saliva was 
measured with the help of AffiniTech SSA or Ro and SSB or La antibodies kit. They 
also compared the result with serological value of SS-A and SSB done by an 
independent clinical laboratory. In their study it was found that serum detection of 
SSA/Ro and SSB/La was more significant than saliva (p=0.001). They found good 
agreement among the results with AffiniTech Kit and independent laboratory (p<0.001) 
but poor agreement between serum and saliva results (p=0.168). 
Hansen et al(33) conducted a study for detection of serum antibodies against 
SSA/Ro and SSB/La in 103 blood donor. They found that in patients with the primary 
Sjogren‘s syndrome who were verified by Copenhagen criteria, 67% were found to have 
Ig G anti SSB antibodies and 71% were found to have anti SSA antibodies. They also 
noticed that all patients who had anti SSB antibodies also showed the presence of anti 
SSA antibodies. The clinical manifestations of pseudolymphoma, Raynaud's 
phenomenon, fatigue and arthralgia, were more common in patients with anti-SS-B/La 
and/or -SS-A/Ro antibodies.
 
Toker et al(34) investigated the presence of the anti SSA and  anti SSB 
antibodies in the tears of patients with Sjogren‘s syndrome and association of these 
antibodies with worsening of keratoconjunctivitis sicca.  He included 28 patients with 
Sjogren‘s syndrome with 17 normal controls and evaluated tear fluid and sera level with 
the help of enzyme linked with immunosorbent assay kit designed for the quantification 
of IgG class autoantibodies directed against highly purified SSA and SSB antigens. They 
found that 57.1% of SS patients showed increased level of anti SSA, whereas 50% of 
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patients were found to have anti SSB in sera. 6 patients have anti SSA in tear fluid, out 
of which 1 was negative for serum antibodies. 10 patients have anti SSB in tear fluid.  
The positive correlation was found between serum and in tear fluid anti SSA and also 
also between serum antibodies and dry eye symptoms score. He suggested the possible 
contribution of these autoantibodies (anti Ro level and anti La) in serum or tear fluid to 
the pathogenesis and severity of the disease.  
Kessel et al (35)investigated and found that anti Ro or La antibodies are good 
substitute to invasive salivary gland biopsy in the patients suspected of suffering from 
Sjogren‘s syndrome. 
Minor salivary gland biopsy:  
Labial biopsy is very specific test for assessment of
 
the salivary component of 
pSS. After the procedure patient
 
may have temporary soreness, but there will be fast 
healing without
 
much scarring. Focal lymphocytic sialadenitis is characteristic 
histopathologic feature
 
of SS. It is defined as multiple, dense aggregates of more than 1 
focus (50 lymphocytes)
 
in the perivascular area or periductal area in the most of sample 
of glands. In patients who are suspected to have persistant swelling of parotid gland due 
to lymphoma, parotid biopsy can be done. 
Nakamura et al(36) did a retrospective study by selecting 112 minor salivary 
gland biopsy(MSGB) cases who fulfilled AECG criteria .He classified the subject into 63 
primary SS with 49 non SS group. With the help of multiple logistic regression analysis 
the diagnosis of the primary Sjogren‘s syndrome was associated with positive.  
Minor salivary gland (MSGB) biopsy (odds ratio (OR) of 105; 95% CI 13, 849), 
positive anti-SSA or Ro antibody (OR 96; 95% CI 10, 923) and the existence of dry eye 
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(OR 8, 95% CI 2, 43). Among the components of the AECG criteria, the major 
contributors are MSGB and anti-SSA/Ro antibody.  
The abnormal finding seen is positive rate in sialography significantly correlated with the 
MSGB grading (P-value for trend = 0.0006), whereas other subjective and the objective 
components were not found to be associated with MSGB grading. 
Guellec et al (37) did systematic review of studies from Pubmed and Embase and 
analysed the sensitivity and specificity of MSGB in pSS. The sensitivity ranges from 
63.5% to 93.7% and specificity ranges from 61.2% to 100%.They failed to find the 
information about the diagnostic role of biopsy as some studies used a set of criteria 
which include MSGB to diagnose pSS. 
 
Clinical Features: 
            It typically manifest as dry eyes (xerophthalmia or keratoconjunctivitis sicca 
(KCS)) and with dry mouth (xerostomia). KCS presents insidiously over a period of 
several years.  
30-70% of patients presents with systemic involvement before or after the 
diagnosis of this autoimmune disease and mostly associated with increased level of anti-
Ro/La antibodies compared to sicca-limited group.  
            Most extraglandular manifestations are presumed to be due to ‗autoimmune 
epithelitis‘ as autoimmune system mainly affects the epithelial cells. Its pathogenesis can 
also be due to vasculitis and/or immune complex deposition, complement activation as in 
skin vasculitis, glomerulonephritis and peripheral neuropathy. 
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Oral manifestation: 
Most of the patients with pSS may not complain of oral dryness, despite 
xerostomia being the most common presentation. Patient may have cracks, soreness, 
difficulty in eating, problem with denture or unpleasant taste. Xerostomia can give rise to 
difficulties to swallow very dry foods without fluid, and need for frequent sips of liquid 
or water, especially at night.  
Antimicrobial properties of saliva are lost which may increase dental caries and 
make the patient prone to oral candidiasis, tooth decay and periodontal infections. 
Swelling of parotids and other xeroses, such as dryness of the nose, throat, skin, and 
vaginal area, can often occur. In SS patients, salivary dysfunction leads to increase in 
number of Lactobacillus and Candida organisms. 
With the progression of the disease oral mucosa become glazed, wrinkles 
formation start and tongue become depapillated and lobulated, taste buds become 
abnormal and there is plaque formation.  
Change in quality of speech (clicking) is noted as because of dryness tongue get 
stuck to hard palate while speaking(38).Oral dryness can severly affects the quality of 
life, affecting the daily activities of living such as eating, sleeping and speaking.   
Chronic or episodic salivary gland swelling which manifest as unilateral 
presentation in the beginning and later becoming bilateral, presents as tender swelling 
and sometimes trismus. This can lead to reduced salivary flow rates and increase risk of 
dental caries. 
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Ocular manifestation: 
Most common ocular presentation of pSS is dry eye. Keratoconjunctivitis(KCS) 
presents insidiously over a period of several years.  Patients of SS describe a ‗gritty‘ 
feeling or ‗sandy‘ feeling in eyes. It can also manifest as gritty sensation, itching, 
redness, soreness, photophobia, eye fatigue, discharge, decreased visual acuity and sticky 
lids.  
Abnormal mucus component of the tear film and decreased secretion of tears 
cause collection of thick mucus secretion along inner canthus. Conjunctivitis, superficial 
corneal erosion and filamentary keratitis are the other presentation. Ocular complications 
includes opacification, vascularization, corneal ulceration and perforation (39). 
 
Fatigue: 
Main symptoms observed is severe debilitating fatigue seen in 50 % of patients 
with pSS. Patients do not feel refresh after sleep and it take a long time for them to get 
sleep. Cause of fatigue is unknown but can be due to subclinical hypothyroidism. 22% of 
patient with SS will have fibromyalgia but  myositis is rarely seen(40)(41). 
Pulmonary involvement: 
Muciod secretions present in the upper and lower respiratory tract will decrease 
in patients with the SS, leading to dryness of the nasal tract, throat, and trachea; which  
may result in symptoms of chronic dry cough. 
It is significant in 10% of the patients and presents as xerosis of nose, 
xerotrachea, interstitial pneumonitis, pseudolymphoma and fibrosis. Subclinical 
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pulmonary disease is seen in 30% of patients (42) as was seen on high resolution 
computerized tomography of chest. Even though disease may have component of small 
airway obstruction, the role of corticosteroid and beta agonist is still controversial. 
 
Renal involvement: 
Renal involvement mainly in the form of interstitial nephritis, which can appear 
earlier than sicca symptoms. Type I and II distal renal acidosis is most commonly 
observed manifestation. Patients may have glomerular lesion, proteinuria, hematuria and 
nephritic syndrome. The development of hypertension and renal insufficiency is  due to 
renal vasculitis (10). 
 
Skin involvement:  
More than 50% of patients presents with dermatological manifestations as dry 
skin, angular chelitis, violaceous discolouration of digits, erythema annulare, chilblain 
lupus, palpable purpura and urticarial vasculitis.in a study 9 to 70% patients with pSS 
had vasculitis of small or medium sized vessels. Only 30% of pSS had mild Raynaud‘s  
phenomenon(39). 
Patients of SS may presents with symptoms of dryness of skin, pruritis, 
hypersensitivity rashes and irritation. 
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Musculoskeletal involvement: 
Intermittent asymmetrical joint pain of small joints is one of commonly reported 
symptoms in (53%) pSS . Joint deformity and erosion are not the usual manifestion but  
typical non erosive arthritis is commonly seen(43). 
 
Gastrointestinal involvement:  
Lymphocytic infiltration of intestine leads to malabsorption. Nausea, epigastric 
pains, dysphagia, esophageal dysmotility and gastritis are other manifestation of the 
disease. Hepatitis mainly autoimmune is found in 1.7% to 4% of pSS patients while 
autoimmune cholangitis is seen in 5 to 10% of patients(44). In patients with Hepatitis C 
infection, xerostomia  is common manifestation but there is absence of dry eyes and 
autonatibodies (anti Ro/SSA).  
Endocrine involvement: 
Hashimoto thyroiditis is seen in approximately 20% of the patients and half of 
them have the subclinical hypothyroidism. Antibodies to thyroid peroxidase and level of 
thyroglobulin suggest the possibility of future development of thyroid disease. 
Haematological involvement: 
Malignanat lymphoproliferation is one of the initial or later manifestation of 
primary Sjogren‘s syndrome and pathogenesis behind this the expansion of monoclonal 
B cells. Localized low to intermediate grade lymphoma of B cell lineage is common 
malignancy seen in SS, and need to managed by combination of chemotherapy. 
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Neurological involvement: 
Sensory polyneuropathies in form of sensory ataxia and small fibres sensory 
painful neuropathy, is one of the major neurological manifestation in pSS. Trigeminal 
and other cranial neuropathy, mononeuritis multiplexa and polyradiculopathy are the 
other neurological presentations. The cause for neuropathy van be due changesin the 
endoneurium microvessel. 
Treatment: 
Ocular involvement, manifested in the form of keratoconjunctivitis sicca, is 
treated with use of local and the systemic stimulators of tear secretion, tear moisture 
replacement like lubricant, methylcelluse inserts and supportive surgical procedures. 
Punctal occlusion either by temporary method (collagen or silicon plugs) or permanent 
method (electrocautery). Supportive measures include use of goggles or glasses with side 
chambers to prevent the existing moisture.  
Treatment of the oral manifestations is done by intense oral hygiene, to prevent 
and treat oral infections, liberal use of saliva substitutes, and by local and systematic 
stimulation of salivary secretion. Cholinergic agents or secretogogues like, pilocarpine 
and use of cevimeline, will be helpful in patients with residual salivary function, and 
ocular drops like cyclosporin seems to be of use in some patients. Systemic therapy with 
immunosuppressives are used for the treatment of the severe extraglandular 
manifestations in Sjögren's syndrome.  
Newer Anti-B-cell therapy is upcoming potential therapy for glandular and the 
extraglandular features, such as vasculitis or glomerulonephritis, in addition to the 
management of the lymphoma which are associated with Sjögren's syndrome. Induction 
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of the oral tolerance and newer gene transfer modalities are recently attempted in some 
animal models, with good results but their utility in humans is still debatable. 
 
Prognosis: 
The lymphoproliferative disease, primarily non-Hodgkin lymphoma is one of the 
most life threatening complication associated with the primary Sjögren syndrome. The 
risk of lymphoma is 40 times more in patients with the primary Sjögren syndrome than 
that in the general population. Various studies have shown lymphoma as a cause of death 
in pSS  on long follow up(45)(46). 
In some patients of Sjogren‘s syndrome who has few adverse prognostic factors 
like purpura, mixed monoclonal cryoglobulinemia and low level of C4 complement, will 
have more rate of mortality. 
 
Tear Film and  its role in Dry eye 
As the importance of the objective tests for estimating ocular dryness has been 
proposed by 2012 criteria(47). So, correct evaluation of  ‗dry eye‘ becomes important in 
the investigation of the patients who are suspected case of the disease,SS.  
Dry eye syndrome is a complex disorder usually referred as a qualitative and 
quantitative alteration of the tear film and patients report subjective symptoms of foreign 
body sensation, burning, itching, redness and photophobia(48). Over many years, 
research has been made in finding out the structural elements of tear film and integrity of 
ocular surface and ultimately to forming the updated concepts about the way in which  
tear film is formed, spread and maintained, and the physiological events leading to the 
development of dry eye.  
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The tear film is subdivided structurally into an anterior most lipid layer, a middle 
thick aqueous layer and an inner one mucin layer. Meibomian glands, goblet cells,  
lacrimal glands, and epithelial cells of the ocular surface help in formation of these 
layers. In the 1980s, the ocular surface was defined to be a functional unit of tear 
(lacrimal functional unit (LFU), whose components are then represented by the lacrimal 
gland, corneal and conjunctival epithelium and goblet cells, tear film and border of 
eyelid with meibomian glands. 
Ocular surface is important for functioning of visual system and act like an 
interface between the outer environment and host. To maintain its functionality 
hydrodynamic factors like eyelid blinking and closure are essential. In 1995, ‗dry eye 
syndrome‘ was described by the Dry Eye Study group (49) as a tear film pathology that 
occurs either due to decreased tear formation or increased evaporation. This leads to 
damage to interpalpebral ocular surface thereby causing various symptoms showing 
ocular discomfort. 
According to DEWS  study(Dry Eye Workshop) 2007 ,the dry eye syndrome is 
described as multifactorial disease of tear and the ocular surface that leads to symptoms 
like discomfort, visual disturbance, and tear film instability associated with potential 
damage to ocular surface itself. It can also lead to increase in osmolarity and 
inflammation of the tear film. 
Tear film is an integrated dynamic system which shows response to pathologic 
events by change in quality and quantity of tear production, increasing proliferation and 
migration of the epithelial cells and by increasing conjunctival vessel permeability.  
Dry eye is known to be a multifactorial disorder that involves various interacting 
mechanisms. Therefore dysfunction of any component can cause dry eye disease by 
alterations in the volume, its composition, the distribution, stability and also the 
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clearance of the tear film. Decreased tear production and epithelial damage along with 
increased osmolarity and instability plays major role. These events start itself as self-
perpetuating and mutually reinforcing the complex global mechanisms, therefore leading 
to ocular surface inflammation and dry eye. These can be associated with abnormality in 
mucus part of tear film leading to ropy discharge. Small erosions on the surface of the 
cornea can be due to dessication. Infections by Staphylococcus aureus can cause 
conjunctivitis.  
 According to DEWS report (50), dry eye disease consists of two major part of  
etiopathogenic groups including evaporative dry eye and also the  aqueous tear 
deficiency dry eye. Hyperevaporative dry eye can be caused due to intrinsic and extrinsic 
ocular causes. Among the evaporative causes, changes are seen in tear film composition, 
eyelid dysfunction, incomplete blinking or decreased blinking rate, ocular surface 
irregularities and drug action. Extrinsic cause includes vitamin A deficiency, topical drug 
preservatives, contact lens wear and ocular surface disease.  
Among the aqueous tear deficient group dry eye can be subclassified as SS and 
non-SS syndrome groups. The latter group has various primary causes, includes absence 
of a lacrimal gland (congenital or acquired), impairment or dysfunction of the lacrimal 
gland, reflex block and drug action. Non-SS dry eye can be due to various conditions. SS 
dry eye is mostly due to the autoimmune inflammation in the lacrimal glands. 
In majority of cases, instances of hyperevaporative and aqueous tear deficient dry 
eye are not so well described clinically but there exist some degree of overlap among the 
two groups. Therefore accurate classification becomes difficult. Subjective assessment 
and objective tests are the diagnostic tool which have clinical utility in tear film 
disorder(51).   
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The disease needs a multidisciplinary approach by an ophthalmologist including 
detailed clinical history about the symptomatology, accurate examination of the patient 
including eyelid anatomy and morphology, blink rate and laboratory tests to lead to a 
conclusive diagnosis. Since there is no perfect test to diagnose dry eyes, variety of tests 
singly as well as in combination are tried. The one which hold major weightage are 
Schirmer‘s test, Tear Break up time test (TBUT) and ocular surface staining score (OSS) 
test as these tests are easy to perform, sensitive and easily reproducible. 
Dye used for staining the ocular surface includes fluorescein dye, Rose Bengal 
and lissamine green. Staining with Rose Bengal causes lot of irritation and discomfort to 
patient leading to its rare use. Lissamine green stain damaged epithelial cells and is very 
sensitive with an added advantage of less discomfort and irritation. Double staining with 
the 1% fluorescein and 1% lissamine can be a useful tool for diagnosis of the  dry eye 
and for evaluating  the therapeutic effect in patients with the dry eye syndrome. 
Kashkouli et al (52) conducted a study to find out the result of Schirmer I test 
done in 5 minutes and in 1 min and proposed that 1 min Schirmer I is faster, comfortable 
and more reliable. He also concluded that Schirmer I test done with open eyes is much 
more reliable than done with eyes closed in patients with dry eyes in Sjogren‘s syndrome 
patient. 
Management of dry eye after diagnosis depends on the cause and grading of 
severity for the condition. Treatment approach should be guided in normalizing tear film, 
decreasing inflammation of ocular surface, stimulating healing of epithelium, with 
improvement in neural feedback system.  
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Treatment should be directed in relieving the sign and symptoms of dry eye, 
protection of tear film and stopping the vicious cycle of inflammation.  
 
Ocular surface disease Index (OSDI) 
It is the one of the best validated questionnaire for dry eye. It consists of 12 
questions for rapid assessment of symptoms of dry eyes and their impact on the vision 
related functioning system. OSDI is assessed on scale ranging from 0 to 100 with larger 
score representing the severity of disability. 
 It has 3 subscales which includes vision related function include 6 questions, 
ocular symptoms including 3 questions and environmental triggers including 3 questions. 
12 items were graded on scale of 0 to 4, where 0 means none of the time, 1 means some 
of the time, 2 means half of the time, score of 3 means most of the time and 4 means all 
of the time. Total scores were calculated using this formula as described OSDI= [(sum of 
score for all questions answered) * 100]/ [(total number of questions answered)*4]. 
Schiffman et al (9)study includes 109 patients with symptoms dry eye and 30 
normal controls who filled OSDI questionnaire and National Eye Institute Visual 
Functioning Questionnairre (NEI VFQ 25) health status questionnaire. They also did 
detailed ophthalmic examination like TBUT, Schirmer and fluorescein and lissamine 
green staining test on these participants. The objective of this study was to determine the 
usefulness as an end point in the clinical trials testing for efficacy of newer treatment for 
dry eyes. The mean OSDI scores were 36 in severe dry eye group, 18 in mild to 
moderate group and 5 in control group. They concluded that OSDI has good sensitivity 
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and specificity which is effective in discriminating normal and various grades of dry eyes 
as defined by physician‘s evaluation of severity and composite disease for severity score. 
Vitale et al (53)examined the association between vision targeted health related 
quality of life i.e  (VT-HRQ) and tear surface parameters which are seen in patients with 
Sjogren‘s syndrome. He included 42 patients selected by AECG criteria and assessed 
results of Schirmer I, vital dye staining tests and questionnaire (OSDI and NEI-VFQ). 
They concluded that there is modest association between objective measures of dry eye 
and questionnaire of VT-HRQ, whereas NEI-VFQ and OSDI was found to have similar 
impact of SS-related dry eye on VT-HRQ. 
 
Differential Diagnosis: 
               The condition which can present with xerostomia includes diabetes mellitus, 
sarcoidosis, amyloidosis, viral infection, psychogenic, trauma or irradiation.  
Dry eye may be seen as a manifestation of amyloidosis, sarcoidosis, inflammation due to 
conjunctivitis, blepharitis, pemphigoid, Stevens-Johnson syndrome, drugs, trauma, 
burns, neurological dysfunction of lacrimal gland, vitamin A deficiency, blink 
abnormality and decreased corneal sensation. 
Parotid gland enlargement (bilateral) may be seen in endocrine dysfunction (like 
acromegaly and gonadal dysfunction), viral infection (like human immunodeficiency 
virus, hepatitis C, mumps), metabolic diseases like diabetes mellitus, pancreatitis, 
cirrhosis and hyperlipoproteinemia.  
The differential diagnosis plays a major role in treatment for systemic manifestation of 
Sjogren‘s syndrome. As most of the autoimmune diseases like SS, SLE, RA, 
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scleroderma has a similar presentation of joint pain, myalgia, low grade fever and 
Raynaud‘s phenomenon, the differentiation can be difficult. The aim of the workup for 
Sjogren‘s syndrome is to eliminate possibility of above mentioned disease and to 
document salient features of SS. This process includes coordination of the multi 
speciality like assessment of eyes, oral cavity and head and neck in addition to 
rheumatologist.  
 
Diagnosis of disease: 
Diagnosing this disease is often difficult. Symptoms are non specific as it 
presents in older age group due to senile atrophy of secreting tissue or due to some other 
cause like use of some drugs. In addition, symptoms of this disease do not presents 
concurrently, thereby denstists, physician and ophthalmologist will treat each symptom 
individually, unknown of the fact that it can be an association of systemic disease. The 
wide diversity of symptoms expression also adds to difficulty in initially diagnosing the 
disease.  
In the past, patients with Sjogren‘ syndrome were commonly misdiagnosed as 
their symptoms were considered to be minor or vague or they may mimic those of the 
other diseases. 
With the help of refined criteria for diagnosis, specialists like rheumatologists, 
dentists, ophthalmologists, physician, who would have only focused only on the 
symptoms of their area of expertise, will be able to get a patient‘s comprehensive image, 
leading to early detection and treatment of the disease. 
None of the laboratory test holds the definitive diagnosis. But, a combination of 
some abnormal test reports is commonly noticed: elevated level of erythrocyte 
sedimentation rate (ESR), anemia, leucopenia and the hypergammaglobulinemia and 
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antibodies like Anti-nuclear antibodies (ANA), anti-Ro or anti-La and the rheumatoid 
factor (RF).  
Systematic multidisciplinary approach is required in proper evaluation of SS, that 
includes assessment of the oral, ocular and systemic components of the disease. 
The widely used criteria include those revised in 2002 by the joint effort by 
research groups in the Europe and in the USA (AECG-American European Consensus 
Group).  
 
AECG- ( American European Consensus Group) 2002 criteria(4) 
I. Ocular symptoms includes a positive response to at least one of following questions: 
1.  Have you had daily, troublesome, persistent, dry eyes for the duration of more than 3   
             months?     
2.  Do you get a recurrent sensation of sand like or gravel in the eyes?     
3.  Do you put tear substitutes for more than 3 times a day?     
II. Oral symptoms includes a positive response to at least one of the following questions: 
1.  Have you had a daily feeling of dryness of  mouth for the duration of more than 3  
             months?     
2.  Have you noticed recurrently or persistently swelling of the salivary glands as an  
             adult?     
3.  Do you frequently drink liquids to help in swallowing dry food?   
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III. Ocular signs- that is, objective evidence of ocular involvement defined as a positive result 
for at least one of the following two tests: 
1.  Schirmer's I test when performed without anaesthesia (≤5 mm in 5 minutes)     
2. Rose Bengal score or other ocular dye score (a score of 4 or more according to van  
            Bijsterveld's scoring  system)     
IV. Histopathology: In minor salivary glands biopsy (obtained through normal-appearing 
mucosa) presence of focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, 
with a focus score ≥1, defined as a number of lymphocytic foci (which are adjacent to 
normal-appearing mucous acini and contain more than 50 lymphocytes) which are present in r 
4 mm
2
 of glandular tissue 
V. Salivary gland involvement: objective evidence of the salivary gland involvement is 
defined by a positive result for at least one of the following diagnostic tests:  
1.  Unstimulated whole salivary flow (≤1.5 ml in 15 minutes)     
2. Parotid sialography showing the presence of the diffuse sialectasias (punctate, cavitary  
            or destructive pattern), without any evidence of obstruction in the major ducts 
3. Salivary scintigraphy which is showing delayed uptake, reduced concentration and/or  
           delayed excretion of tracer     
VI. Autoantibodies: presence in the serum of the patients, the following autoantibodies: 
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both     
Revised rules for classification 
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For primary SS 
In patients without any potentially associated disease, pSS may be defined as follows: 
a. The presence of any 4 of the 6 items is  indicative of pSS, as long as either item IV  
            (Histopathology) or VI (Serology) is positive  
b. The presence of any three of the four objective criteria items (that is, items III, IV,     
            V, VI)     
 
Secondary SS: 
In the presence of some another connective tissue disease, presence of the item I 
or item II, with addition of any two from items III,item IV and V  
 
Exclusion criteria: 
Previous history of head and neck radiation therapy, hepatitis C infection, 
infection like AIDS, pre existing lymphoma, and sarcoidosis, graft versus host disease, 
use of anti-cholinergic drugs ,since  time shorter than fourfold of the half-life of drug. 
Recently, the SICCA (Sjögren‘s International Collaborative Clinical Alliance) 
presented a new expert consensus approach in which classification criteria based entirely 
on objective measures(47). In this criteria, not only ocular symptoms and oral symptoms 
have been excluded, but also the study of minor salivary gland involvement has been 
removed from the criteria. 
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SICCA criteria(47) 
 (I) Ocular signs  
Keratoconjunctivitis sicca with ocular staining score ≥ 3, according to the 
Whitcher et al i.e preferential use of the fluorescein staining or lissamine green staining, 
but tear break-up time; and  non anesthetized Schirmer I test can also be used. It is 
presumed that individual is not currently using some daily eye drops for glaucoma and 
who has not had corneal surgery or any cosmetic eyelid surgery in the last 5 years). 
(II) Histopathology of biopsy of minor salivary gland : 
Focal lymphocytic sialoadenitis, with focus score ≥ 1 i.e a focus is defined as the 
presence of 50 or more lymphocytes per 4 mm
2
 of glandular tissue adjacent to the normal 
appearing mucous acini) 
(III) Autoantibodies: 
Positive serum anti-SS-A or Ro and/or anti-SS-B or La or (positive rheumatoid 
factor and anti-nuclear antibody (ANA) titer ≥ 1:320) 
Classification criteria includes:  
At least two of the three items in order to classify a patient as SS 
 
Exclusion Criteria: 
History of head and neck radiation treatment, hepatitis C infection, AIDS, sarcoidosis, 
amyloidosis, graft versus host disease, IgG4-related disease. 
 
Literature suggests various criteria to diagnose the disease based on clinical, 
pathological and laboratory finding. Modified AECG criteria(54) appear to the most 
widely used as it takes into their consideration the multisystem nature of this disease; the 
criteria includes the ocular and the oral signs and symptoms, antibodies to SSA and SSB 
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and labial salivary gland biopsy. Patient should meet 4 out of 6 proposed items including 
a positive lip biopsy or positive serology for antibodies.  
AECG criteria have the disadvantage of inclusion of the subjective tests 
(symptoms), kind of physiologic measures which lacks specificity and alternative 
objective tests which are not diagnostically equivalent. Further the inclusion of these 
symptoms of dry mouth and /or dry eyes can lead to misclassification of the 
asymptomatic patients. Alonwith it, physiologic measures, such as unstimulated whole 
salivary flow (UWS), anaesthetized Schirmer test and the salivary scintigraphy, are very  
useful for assessment of salivary or tear function, but lack the specificity for SS. 
Measurement of unstimulated salivary flow is done with help of sialometry that is 
by collection of saliva in a calibrated tube for duration of 15mins. Normal flow defined 
is 1.5ml. It is a simple and a noninvasive procedure, but doesnot help to distinguish 
between various causes of xerostomia. Other tests include  salivary gland schintigraphy 
and parotid sialography. 
ACR criteria(6) require two out of 3 components – including labial biopsy, anti 
Ro/anti La antibodies and OSS. It does not include subjective symptoms of dry eye/dry 
mouth. A diagnosis of SS when in its early stages has potential clinical relevance, but it 
is difficult and cannot be made alone on the clinical grounds. 
            Hay et al (1)conducted a population based study on 341 patients, out of which 
44.6% were male and 55.4% were female with a median age for male was 46 years and 
for female it was 49 years. 96% of the patients had ocular symptoms. Overall the 
commonest ocular symptom was ―smoke irritates the eyes‖, reported by 58% followed 
by ―sand or gravel sensation‖ in 22%. 
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Schirmer test was found to have sensitivity of 0.77 and specificity of 0.72 in 
hospital setting against the clinician ―gold standard ‖ diagnosis of Sjogren‘s syndrome 
but in other study it was found to have poor reproducibility (55) making it less valuable 
clinically. For Schirmer test with wetting of 5 mm or less when measured over five 
minutes under the basal conditions with the eyes slightly closed was considered to be 
abnormal. Tear Break up time (TBUT), which was found to be a simpler test to measures 
tear film stability but need slit lamp for evaluation. Measurement of antibodies to the Ro 
and La was done by ELISA in blood sample (Shield Diagnostics), and anti-Ro and anti-
La > 2 U/ml were defined as abnormal. 
No association was seen between presence of autoantibody and either symptoms 
or signs of dry eyes or dry mouth. Strongest association was found in subjects with both 
the ocular and oral symptoms and objective results. He found a weak association 
between the presence of oral symptoms or ocular symptoms and the test results of USF 
(unstimulated salivary flow) or Schirmer I. They examined the association separately for 
the subjects less than and over 55 years of age and reported higher frequencies of the 
abnormal findings in the elderly. This was thought to be due to age related changes 
causing dysfunction of lacrimal and salivary glands. Ocular symptom in elderly was 
assumed to be probably due to other causes like blepharitis thereby not giving an 
abnormal Schirmer test. 
The limitation of this study was selection bias as only 55% subjects agreed to 
participate in the study, low prevalence of the affected subjects in that community 
compared with hospital sample with decreased frequency of dry eye and dry mouth 
complaints. This study also lack standardisation, leading to high false positive result and 
low predictive value. 
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Jacobsson et al (56) studied 705 subjects of age group 52 to 72 years and 
randomly did serologic testing and other exocrine gland function measuring tests on 
symptomatic (n=77) and asymptomatic subjects (n==32). He has found that the high 
levels of antibodies to Ro and La antibodies, in a population with symptoms of dry eyes 
or dry mouth and impaired exocrine gland function on the objective testing but the 
difference was very small and may not be clinically significant. 
 
 Tsuboi et al (2) studied 694 subjects with Sjogren‘s syndrome(SS) or 
suspected SS from 10 hospitals to validate their revised Japanese Ministry of Health 
criteria (JPN) (1999), AECG (2002), ACR (2012). Out of 476, 302 were pSS and 218 
was non SS. The sensitivity of JPN criteria to all forms of SS (79.6%) and secondary SS 
(75.3%) was highest.  The sensitivity for primary SS (83.1%) was highest with AECG.  
The specificities of JPN and AECG criteria for all forms of SS, primary SS, and 
secondary SS were highest in the diagnosis of SS in Japanese patients. The gold standard 
was clinical diagnosis by physician. The JPN criteria (1999) were intended to help in 
diagnosis, whereas the AECG (2002) criteria and the ACR criteria (2012) were useful in 
classification used in clinical studies and trials. Moreover, ACR criteria may not identify 
patients who have negative result for labial biopsy as it does not include analysis of 
salivary secretion and imaging results. AECG includes oral and ocular symptoms and 
can give false positive results in non Sjogren subjects due to aging or visual display 
terminal syndrome. 
         Their study suggested JPN criteria to be superior to other two criteria in diagnosis 
of Sjogren‘s syndrome in Japanese patients. But JPN criteria are not validated by ACR 
and EULAR, so it is only used in Japan. 
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Vitali et al (57) conducted a study on 447 European patients with Sjogren‘s 
syndrome and 246 controls, to establish a diagnostic criteria by performing a series of 
oral and ocular tests, parotid sialography and minor salivary gland biopsy. The most 
common ocular symptom found in this study was feeling of dry eye or ‗sand in the eye‘ 
and most common oral symptom was feeling of dry mouth while eating or breathing. 
Among the ocular test, Schirmer test showed best balance between the sensitivity and 
specificity (76.9% and 72.4% respectively). Staining with Rose Bengal was found to be 
most specific (81.7 %). Tear film lactoferrin level and break up time showed unreliable 
results especially in Primary Sjogren‘s syndrome. The results of these tests vary with the 
age and type of Sjogren‘s syndrome. However the study concluded the positivity of these 
tests along with presence of the  subjective symptoms and the serological abnormalities 
forms the accurate diagnosis. 
Martin and Martin et al (58) developed a simple mathematical score which 
uses clinical and the laboratory variables for diagnosing the SS, thereby reducing  need 
of the minor salivary gland. The following variables were used in their model: ANA 
antibody, SS-A/SS-B antibody, Schirmer test/TBUT, C3/C4, serum gammaglobulin 
level. Then, one hundred consecutive individuals who were reporting clinical syndromes 
consistent with sicca syndrome were included in their study. The application of these 
multifactorial and mathematical model was shown to have the high predictive value for 
SS versus the controls or versus the patients with other autoimmune disorders 
(Sensitivity 93%, Specificity 100%), with an estimated minor salivary gland reduction of 
77%. They proposed that mathematical model can be considered as useful non-invasive 
approach in diagnosing Sjogren's syndrome and recommended that its validation to be 
done on a larger scale.  
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Akpek et al (59) conducted a retrospective study on 220 patients of dry eye 
syndrome, out of which 10.9% were found to have pSS .Only 33.33% carried diagnosis 
of pSS at initial presentation. On initial evaluation 66.66% were positive for anti 
SSA/anti SSB and those who were serology negative (16.7%) showed positivity with 
minor salivary gland biopsy. He concluded to focus on diagnostic evaluation of pSS 
which remain underdiagnosed in many patients of dry eye syndrome. 
Galvez et al (60)did study on 88 patients who underwent labial biopsy with 
clinical suspicion of Sjogren‘s syndrome and analysed that the preliminary European 
criteria has higher sensitivity but lesser specificity than AECG criteria. 
Brun et al (61) investigated 203 patients with a clinical diagnosis of Sjogren‘s 
syndrome. 88.8% had MSGB done and 99.5% had information about autoantibodes. He 
used cut off for Schirmer as 5 in 5 minutes and also took salivary gland tests into 
account. Mean age group found was 55 years and 96.4% was female. He concluded that 
only 40.9% patients satisfied the proposed modified European criteria that include the 
presence of either antibody or salivary gland biopsy positive. This study concluded that 
approximately one-third of patient who have an established diagnosis by preliminary 
European criteria, will lose the diagnosis according to modified criteria and the use of 
immunological variables and histopathology of salivary gland will be premise for 
diagnosis. But the proposed modified criteria, if used by scientific community and 
research will lead to comparable population SS patients and prove it to be an 
autoimmune related systemic disease.  
Versura et al(62) collected clinical and the cytological data from 177 patients 
who need to be evaluated for diagnostic performance of the test that are included in 
Sjogren‘s syndrome diagnostic criteria. Out of the 62 patients with Sjogren‘s syndrome, 
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5patients were male with mean age group of 56.1±10.2 years and 57 were females with 
mean age group of 61.6±10.8 years. This study revealed poor diagnostic accuracy of 
Schirmer I test (sensitivity=0.42; specificity= 0.76; LR +1.11; area under the curve in 
ROC analysis < 0.412), TBUT though showed poor performance (with sensitivity of 0.92 
but specificity of 0.17; LR +1.11 and area under ROC curve 0.59) can exclude diagnosis 
of pSS but with low specificity. Validated subjective symptoms questionnaire (sensitivity 
0.89 and specificity 0.72; LR+3.18; area under curve 0.896), Jones test, measurement of 
corneal sensitivity with corneal aesthesiometry and the tear clearance test showed high 
diagnostic performance. Lissamine green showed best performance (sensitivity of 0.63 
and specificity of 0.89; LR of +5.72) with statistically significant difference between pSS 
and other groups. But the limitation of this study was incorporation bias for Schirmer 
test. 
Barboza et al (63) studied 17 patients with Sjogren syndrome and 25 normal 
controls. Ocular surface disease index (OSDI) questionnaire was used for symptom 
assessment and ocular signs were tested using Schirmer I and II, ocular surface staining 
with Rose Bengal dye, pachymeter and aesthesiometer. This study showed a weak 
correlation between the symptoms of patients with Sjögren's syndrome and ocular signs 
that indicate disease severity concluding that all symptomatic patients did not showed 
positivity for corresponding tests. This weak correlation was attributed to variation in 
corneal sensitivity. All other parameters studied in the disease group showed statistically 
significant (< 0.05) difference in comparison to control group.  
Markusse et al (64)did a study on 44 (40 men and 4 women with a mean age 
group of 55 years) randomly selected primary Sjogren‘s syndrome subjects and found 
that ocular involvement was present in 42 patients. 21 patients were clinically suspected 
as pSS but on the basis of ophthalmology evaluation, diagnosis was excluded .He 
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concluded that there is limited role of Schirmer, Rose Bengal staining and tear film break 
up time in diagnosis the disease.  
Nichols et al (65) conducted a study on 75 patients with dry eye disease selected 
with non specific criteria by clinician. Patients were interviewed regarding symptoms of 
dry eyes and underwent ophthalmological examination like tear meniscus height, TBUT, 
Schirmer test, Rose Bengal staining, fluorescein and phenol red test. They found a poor 
correlation between symptoms of dry eyes and their tests after adjustment for age and 
use of lubricants. 
Bjerrum et al (66) compared results of the dry eye test and symptoms in patients 
with the primary Sjogren‘s syndrome ,secondary SS and normal controls. Schirmer value 
and TBUT below10mm/5mins and 10 secs respectively , had high sensitivity and low 
specificity, but Rose Bengal and Schirmer less than 5mm/5mins showed reverse results. 
There was variability in test on repeated visits. They concluded that in case of test 
negative but with symptoms of pSS, examination of Keratoconjunctivitis sicca should be 
repeated.  
Yoon et al (67) concluded that nasal conjunctiva has more staining compared to 
the temporal conjunctiva and staining of cornea (p = 0.04). And this staining pattern of 
the nasal conjunctiva showed a significant correlation with the OSDI score (p < 0.01) 
and TBUT (p = 0.03). Staining of temporal conjunctiva showed significant corelation 
with ocular symptoms (p of 0.01), and the staining of cornea correlated with TBUT (P of 
0.02). This study proposed the strong correlation of double vital staining (1% lissamine 
and 1% fluorescein) with symptoms and the ocular surface parameters in those patients 
with dry eye, thereby helping us to identify ocular surface changes easily.  
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Whitcher et al (68) studied SICCA cohort of 1208 patients and promotes the use 
of two different vital dyes for grading different areas of ocular surface as the key 
diagnostic parameter in KCS. Patients were divided into two KCS subgroups: KCS only 
and SS-KCS group. 
Among participant with KCS only, the median OSS (Ocular staining score) was 5 
compared to 9 among those with the SS-KCS with statistically significant difference 
between 2 subgroups (p<0.0001). This study also showed significant difference in 
Schirmer I and TBUT among 2 subgroups with no difference in symptoms of dry eye or 
dry mouth. He also introduced OSS score which include (stepI) fluorescein  staining 
pattern of the cornea to count for punctuate epithelial erosions(PEE) and lissamine green 
staining pattern of the conjuctiva(Step 2).It was considered to be a diagnostic tool as well 
as to monitor the response to treatment. The total OSS is the summation of staining of 
corneal fluorescein score and the staining of lissamine green scores for nasal and 
temporal bulbar conjunctiva. Hence, the maximum score possible for each eye is 12.  An 
OSS score higher than 0 is supposed to be an abnormal and can be a sign of KCS. And 
the scores of 1 or 2 can also represent the late staining artifact if there is delay in 
interpretation of fluorescein corneal staining pattern. Because it can lead to a significant  
high level of misclassification, an abnormal OSS score is defined as being  score of 3 or 
above. 
Paschides et al (69) conducted a study on 81 primary Sjogren‘s syndrome and 
276 normal control. Mean value of TBUT in pSS group was found to be 7± 3 and in 
control group 13±6.Schirmer I test showed a mean value of 10±9 in normal group and 
4±7 in pSS group. Rose Bengal was found to be the best test in their study with a mean 
of 5±2 in pSS and 1±1 in normal group with statistically significant difference in 2 
groups. 
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Adatia et al(70) examined the hypothesis that the reduction in corneal sensitivity 
is associated with the increased ocular surface disease and reduction of symptoms in 
patients with Sjogren‘s syndrome. He assessed 18 subjects who are diagnosed to have 
Sjogren‘s syndrome with OSDI questainnaire and Symptom Severity of 
Discomfort(SSD) scale along with ophthalmological examination including corneal 
esthesiometer, fluorescein stain and lissamine green staining, Schirmer I and TBUT. 
Both lissamine green and fluorescein showed negative correlation with the central 
corneal sensation (r of -0.3542, p value of 0.034) indicating the reduction of corneal 
sensation with increased ocular surface disorder. He also concluded that patients with 
pSS have less symptoms with increased corneal disease as depicted by advanced corneal 
staining.  
Liew et al (71) conducted study on 327 patients and concluded that patients with 
SS had the worse corneal and the conjunctival staining and Schirmer I test compared to 
patients with Non Sjogren‘s syndrome.  
Numerous criteria have been described to facilitate the diagnosis of SS and no 
consensus has been reached yet, even though there is requirement for the definitive set of 
a diagnostic criteria.  
In our study subjective symptoms of patients suspected of SS-I will be assessed 
by validated of OSDI (Ocular Surface Disease Index) questionnaire(8)(9).The purpose of 
this study is to evaluate the diagnostic performance of Schirmer I test, TBUT and OSS 
test in SS-I patients by assessing the sensitivity, specificity and likelihood ratio of each 
test performed. This study will also aim to correlate between ocular symptoms, signs, 
immunological variables and labial salivary gland biopsy. Schirmer I of 5mm or less 
in 5 mins, TBUT of less than 10 secs and OSS score of 3 or above will be considered as 
abnormal. 
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In this study we will evaluate diagnostic accuracy of dry eye tests in Primary 
Sjogren‘s syndrome in the Indian setting which can be endorsed by clinician across the 
world to increase their credibility and also to maximize standardization when enrolling 
patients into the clinical trial. This study will also help in early suspicion of the disease 
and its timely management. 
 53 
 
 
 
 
 
 
 
 
 
 
 
RESULT AND ANALYSIS 
 54 
 
RESULT AND ANALYSIS 
 
There were 95 patients who were recruited for the study after applying the 
inclusion and exclusion criteria. 
Sex distribution of patients 
Out of 95 patients; 5 were males and 90 were females. 
94.7%
5.3%
Sex distribution of patients
females
males
 
Fig.1 Sex distribution of patients 
Age distribution of patients 
 The patients were in age group of 18 to 71 years; 
 3 patients were less than 20 years, 31 patients were between 21-40 years, 54 were 
between 41-60 years and 7 were between 61-80 years. 
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 Mean age group of the patients was 43.74 years. Mean age group among female 
patients was calculated to be 43.54 years and mean age group among male patients was 
found to be 47.20 years. 
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Fig2. Age distribution of patients 
 
Occupation of the patient: 
 Out of total patients recruited in the study, 69.5% were housewives, 18.9% were 
students, 7.4% were working in an office without air conditioner (AC) and 3.2% were 
working in office with an AC. 
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Fig.3 Occupation of patients 
 
Chief complaints: 
Of the 95 patients, 86 (90.5%) patients had ocular complaints. The mean duration 
of symptoms was 2.15 years with a minimum of 1 month and maximum of 96 months. 
There was no difference in the duration of symptoms between male and female patients.  
 Patients presented a range of symptoms that included sandy eyes, gritty 
sensation, itching, redness, stickiness, photophobia, vision disturbance and cheek 
swelling (parotid enlargement). The most common symptoms were itching and foreign 
body sensation. 
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 56.8% patients complaints of itching and foreign body sensation in their eyes, 
49.5% complaints of burning eyes, 33.7% have feeling of dryness in eyes, 22.1% 
complaints of sticky sensation, 10.5% have vision disturbance, 6.3% have complaints of 
redness in their eyes. Most of the symptomatic patients have more than 1 complaint. 
 
0.00%
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Complaints of patients
Series 1
 
Fig.4 Complaints of patients 
 
Visual disturbance was seen in 10 patients who were in the age group of 50 to 65 
years. 57% of symptomatic patients were using lubricant eye drops. 
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 3% patients give history of use of systemic anticholinergic drugs, 72 % patients 
denied use of anti cholinergic drug and the remaining 25% did not have the complete 
details of systemic medication used. 
Blood tests results of the patients.  
Anti SS- A antibodies tests was done in ninety two patients and anti SS-B was 
done in fourty nine patients out of total study population of ninety five 
 
Table 1.  Blood tests results of the patients 
Tests Positive Negative Total Not done 
Anti SS-A 30(32.60%) 62(67.39%) 92(100%) 3(3.15%) 
Anti SS-B 11(22.44%) 38(77.55%) 49(100%) 46(48.42%) 
Labial Biopsy 37(39.36%) 57(60.63%) 94(100%) 1(1.05%) 
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Anti SSA antibody: 
Of the 92 patients, 30 (32.60%) patients had positive anti SS-A titre (>20Ru/ml) 
and 62 had negative titre.  
Out of the 30 patients who were positive for anti SSA, 23 patients (76.70%) were 
finally diagnosed to have primary Sjogren‘s syndrome.  
The sensitivity and specificity was 76.7% and 88.7% respectively. The positive 
predictive value of anti SSA is 76.7%. 
3
62
3
27
Anti SSA results
anti SSA+ (NON SS)
anti SSA -
Not done
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Fig. 5 Anti SSA results 
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Anti- SSB antibody: 
Out of 49 patients who got the test done, 11 (22.44%) patients were found to be 
positive for anti SS-B titre (>20Ru/ml) and 38 patients were found to have a negative 
titre. 
All the 11(100%) patients who were having anti SSB positive titre were 
diagnosed to have pSS.  
The sensitivity and specificity was found to be 52.4% and 73.7% respectively. 
The likehood ratio and positive predictive value could not be calculated as it represents 
very small part of the sample population. 
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Fig.6 Anti SSB results 
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Labial Biopsy: 
Out of 95 patients who were included in the study, 94 patients had labial biopsy 
done. 37(39.36%) patients were found to be positive for labial biopsy (grade IV 
inflammation) and 57 (60.63%) patients showed negative result. 
Out of the 37 biopsy positive patients, 30 (81.08%) of them were diagnosed to 
have primary Sjogren‘s syndrome.  
  The sensitivity and specificity of MSGB was found to be 96.8% and 88.9% 
respectively. The positive predictive value of biopsy was found to be 81.1%. 
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ACR criteria for diagnosis of Sjogren’s syndrome: 
Out of 95 study patients, 31 patients were diagnosed to have primary Sjogren‘s 
disease (pSS) as per ACR criteria.  
            According to this criteria, 14 patients were included as they have anti SSA titre 
and labial biopsy positive test result, 8 patients have all 3 (anti SSA, anti SSB and labial 
biopsy) positive, 2 patients had anti SSB titre and labial biopsy positive and 1 patient had 
anti SSA titre and anti SSB titre positive, 6 patients were included as they have labial 
biopsy positive result and OSS ≥3.  
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Fig.8 ACR criteria for diagnosis of PSS 
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 NUMBER AND PERCENTAGE OF POSITIVE TEST RESULTS OF   
                  OSDI, SCHIRMER TEST, TBUT and OSS  
                      (in patients with pSS and Non SS group) 
 
Ocular surface disease index (OSDI): 
43 patients have an OSDI score below 18, 49 patients were having the score in 
the range of 18-36 and 3 patients were having score of more than 36. The number of 
primary Sjogren syndrome patient found in the range of normal, mild to moderate and 
severe were 8, 20 and 3 respectively. 
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Fig.9 Distribution of OSDI 
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Schirmer I (Sch-I) tests: 
8 patients of pSS group were found to have Schirmer value 11-15mm compared 
to 13 patients of Non SS group.  Schirmer value of 6- 10mm were seen only in 12 
patients of pSS group and only 4 patients of the Non SS group, but Schirmer value of ≤ 
5mm was seen only in 3 patients of pSS and was not seen in any patient of the control 
group.  
Table 2 Distribution of Schirmer test 
 
 Schirmer 11-15mm 
(total=21) 
Schirmer 6-10mm 
(total=16) 
Schirmer ≤5mm 
(total=3) 
pSS 8/31= 25.8 % 12/31= 38.70% 3/31= 9.67% 
Non SS 13/64= 20.31 % 4/64= 6.25% 0/64= 0% 
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Fig.10 Distribution of Schirmer test 
 
TBUT tests 
TBUT value of 8-10 secs was seen in 6 patients of pSS group and in 38 patients 
of the Non SS group. TBUT value of 6-7secs was seen in 23 patients of pSS group and 
24 of control (Non SS) group.  TBUT ≤ 5secs was seen only in 2 of the patients of pSS 
group and was seen in 1 patient of the control group (Non SS).  
Table 3, Distribution of TBUT 
 TBUT 8-10 secs 
(total=44) 
TBUT 6-7 secs 
(total=47) 
TBUT ≤ 5 secs 
(total=3) 
pSS 6/31=19.35% 23/31=74.19% 2/31=6.45% 
Non SS 38/64=59.37% 24/64=37.5% 1/64=1.56% 
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Fig.11, Distribution of TBUT 
 
Ocular staining score (OSS) 
OSS score of 6 or more was seen in 2 patients of pSS group and in only 1 patient 
of Non SS group. OSS score of 3-5 were seen in 17 patients of pSS group and 5 patients 
of Non SS group.OSS less than 3 was seen in 12 patients of pSS and most (58 patients) 
of the control group.  
Table 4, Distribution of OSS 
 OSS ≥6 
(total=3) 
OSS 3-5 
(total=22) 
OSS < 3 
(total=70) 
pSS 2/31=6.89% 17/31=54.8% 12/31=41.38% 
Non SS 1/64=1.15% 5/64=7.08% 58/64=87.88% 
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Fig.12, Distribution of OSS 
 
OCULAR SUFACE DISEASE INDEX: 
Ocular symptoms as expressed by Ocular surface disease index (OSDI) are 
presented by numeric value ranging from mild in Non SS groups to mild to moderate in 
pSS group. Medium values of OSDI seen in pSS patients were 24.60±9.36 and in Non 
SS patients were 17.8±5.3, with statistically significant difference (p< 0.001) between 
two groups. 
Dry eye symptoms in varying severity were present in almost all patients who are 
suspected of having the disease (p<0.015). 
The median value and the interquatile range for OSDI score in both the pSS 
group and the Non SS group is shown in the box plot in figure 13: 
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Table 5, Interquartile range and min-max values for OSDI score 
 
 
 
 
 
 
Fig.13, Box plot showing Median value, results from 25-75% and range min-max 
values for OSDI 
Percentile SS group Non SS group 
25 16.6700 13.63 
50 22.2200 16.63 
75 31.2500 21.63 
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  To calculate the hinge point or the cutt off range for OSDI score ROC curve was 
use which shows the balance between its sensitivity and specificity as shown in figure 14 
below. 
  In our study OSDI score for 18.7 showed a sensitivity of 71% and specificity of 
65.00% and ROC plot anaysis demonstrate a curve approaching irregularly near the 
diagonal line, with area under the curve 0.718. 
 
Fig. 14, ROC curve for OSDI 
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Table 6, Area under the curve for OSDI 
 
Asymptotic 95% Confidence 
Interval 
Area Std. Error
a
 
Asymptotic 
Sig.
b
 Lower Bound Upper Bound 
.718 .059 .001 .602 .835 
 
SCHIRMER TEST: 
Schirmer I (Sch-I) are expressed in mm/5minutes. According to box plot, median 
values of decrease in tear production seen in pSS patients were 12.77±5.37 mm/5mins 
and in Non SS patients were 19.21±4.97mm/5mins, with statistically significant 
difference (p< 0.001) between two groups. 
Median value of pathological Schirmer I test of ≤ 5mm/min was seen in only 3 
patient of pSS group and none of the patients of Non SS groups. The sensitivity and 
specificity for Sch-I ≤ 5 was found to be 19.4% and 96.9%. Hence concluding that the 
mean value of tear secretion is supposed to be higher than pathological threshold(≤ 
5mm/5mins) between 2 groups.  
For the cut off value of Schirmer I ≤ 15mm, the sensitivity and specificity was 
found to be 64.5% and 85.90% respectively. The positive predictive value was 69% and 
positive likelihood ratio was 4.57. 
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Table 7, Interquartile range and min-max values for Schirmer I  
 
 
  
 
 
 
Fig.15 Box plot showing median value of Schirmer I in pSS group and Non SS 
group 
Percentile SS group Non SS group 
25 10.00 15.00 
50 12.00 20.00 
75 17.00 22.00 
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In the above box plot (figure 15) the median value of the Schirmer I in diseased 
population of pSS group  is around 12.7mm and in the control group of Non SS group 
population is 19.2mm. 
ROC plot analysis demonstrate a curve approaching to upper left corner of the 
graph ,with area under the curve 0.779 suggesting the balance between sensitivity and 
specificity at Schirmer I value at 15mm. 
 
                               Fig.16, ROC curve for Schirmer I test  
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Table 8, Area under the curve for Schirmer I test 
 Asymptotic 95% Confidence Interval 
Area Std. Error
a
 Asymptotic Sig.
b
 Lower Bound Upper Bound 
.807 .049 .000 .711 .904 
 
Tear breakup time (TBUT)  
It is expressed in seconds. Medium values in pSS patients were 6.6±1.04 secs and 
in Non SS patients were 7.87±1.24 sec with statistically significant difference (p< 0.001) 
between two groups.  
For a value of TBUT≤10 sec, the sensitivity and specificity was found to be 
96.8% and 12.5%. The positive predictive value was 34.9%.  
But the pathological cut off value,for a good sensitivity and specificity comes to 
around TBUT≤ 8 secs, the sensitivity and specificity was found to be 80.6 % and 60.90% 
respectively. The positive predictive value was 50% and the positive likelihood ratio was 
2.06. 
Table 9, Interquartile range and min-max values for TBUT 
 
 
 
Percentile SS group Non SS group 
25 6.00 7.00 
50 6.00 8.00 
75 7.00 8.00 
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Fig.17, Box plot showing median value of TBUT test in pSS group and Non SS 
group 
In the box plot shown above(fig 17), median value of TBUT in pSS group is 
6.6secs except for one patient whose TBUT value is around 10 secs, whereas in Non SS 
group ther is variability in range of TBUT,with a median value of 7.8 secs, 4 patients 
having a value of 10 secs or more and only 1 patient have a TBUT of around 5secs.
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                ROC plot in figure 18, demonstrate a curve approaching to upper left corner 
with area under the curve 0.780 suggesting the balance between sensitivity and 
specificity at TBUT ≤8 secs. 
 
                                   Fig.18, ROC curve for TBUT test 
Table 10, Area under the curve TBUT 
 Asymptotic 95% Confidence Interval 
Area Std. Error
a
 Asymptotic Sig.
b
 Lower Bound Upper Bound 
.780 .052 .000 .679 .881 
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In figure 19, ROC curve shows a comparison between the Schirmer I and TBUT, 
demonstrating a close similarity between both the graph with Schirmer I curve having 
slightly more area under the curve than TBUT.  
 
Fig.19, ROC curve showing the comparison of TBUT and Schirmer I 
Table 11, Area under the curve of TBUT and Schirmer - I 
Test 
Result 
Variable(s) 
 Asymptotic 95% Confidence Interval 
Area Std. Errora Asymptotic Sig.b Lower Bound Upper Bound 
Lsch .807 .049 .000 .711 .904 
Ltbut .780 .052 .000 .679 .881 
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Ocular Surface staining (OSS) score: 
It is presented in numeric value. Medium values in pSS patients were 2.48±1.84 
and in Non SS patients were 0.84±1.19, with statistically significant difference (p< 
0.001) between two groups. 
 For the cut off value of OSS ≥3, the sensitivity and specificity was found to be 
61.3% and 90.60% respectively. The positive predictive value was 76% and positive 
likelihood ratio was 6.52. 
Table 12, Median value,results from 25-75% and range min-max values for OSS  
Percentile SS Group Non SS Group 
25 1.00 0 
50 3.00 0 
75 4.00 1 
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Fig.20, Box plot showing median value of OSS score in pSS group and Non SS 
group 
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Fig.21, ROC curve for OSS score 
Table 13, Area under the curve for OSS  
 Asymptotic 95% Confidence Interval 
Area Std. Error
a
 Asymptotic Sig.
b
 Lower Bound Upper Bound 
.766 .056 .000 .655 .876 
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Table 14, Association between subjective symptoms and objective tests  
Correlations 
   
OCULAR 
SURFACE 
DISEASE INDEX 
Lsch 
Spearman's rho OCULAR SURFACE DISEASE 
INDEX 
Correlation Coefficient 1.000 -.397
**
 
Sig. (2-tailed) . .000 
N 95 95 
Lsch Correlation Coefficient -.397
**
 1.000 
Sig. (2-tailed) .000 . 
N 95 95 
ltbut Correlation Coefficient -.341
**
 .769
**
 
Sig. (2-tailed) .001 .000 
N 95 95 
max_oss Correlation Coefficient .285
**
 -.652
**
 
Sig. (2-tailed) .005 .000 
N 95 95 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
Fig.22, Scatter plot showing association between Schirmer I and OSDI  
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There is modest negative correlation as shown in figure 22 ,between subjective 
symptoms depicted by OSDI and Schirmer I test value, with correlation coefficient of -
0.397 and p<0.001. 
 
Fig.23, Association between TBUT and OSDI 
 
There is modest negative correlation between subjective symptoms depicted by 
OSDI and TBUT test value, with correlation coefficient of -0.341 and p<0.001 as shown 
in figure23. 
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Fig.24, Association between OSS and OSDI 
 
There is modest positive correlation between subjective symptoms depicted by 
OSDI and Schirmer I test value, with correlation coefficient of +0.285 and p<0.001 as 
shown in figure 24. 
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CORELATION BETWEEN IMMUNOLOGICAL VARIBLES (ANTI-SSA AND 
ANTI-SSB) WITH OBJECTIVE TESTS (SCHIRMER I, TBUT, OSS) 
Corelation of anti SSA  : 
Corelation of anti SSA value with Schirmer I test,TBUT and OSS suggests a 
positive likehood ratio of 1.86,2.48 and 1.90 respectively 
Table 15, Corelation of anti SSA value with Schirmer I test,TBUT and OSS 
 Sensitivity(%) Specificity(%) PPV(%) +LR 
OSDI 60 60.32 41.86 1.51 
Schirmer I 46.7 75.8 48.3 1.92 
TBUT 63.3 51.6 38.8 1.31 
OSS 40 79 48 1.90 
 
Table 16, Corelation of anti SSA value with Schirmer I test,TBUT and OSS 
Statistics 
ANTI SSA 
OCULAR 
SURFACE 
DISEASE INDEX 
max_oss lsch ltbut 
Positive N Valid 30 30 30 30 
Missing 0 0 0 0 
 Mean 23.2780 1.70 15.1667 7.1667 
Std. Deviation 8.83059 1.557 5.71196 1.23409 
Minimum 10.71 0 5.00 6.00 
Maximum 43.50 4 25.00 10.00 
Percentiles 25 16.6450 .00 10.0000 6.0000 
50 22.2200 1.00 15.0000 7.0000 
75 29.2625 3.00 20.0000 8.0000 
Negative 
 
 
 
 
 
 
 
 
 
 
N Valid 62 62 62 62 
Missing 0 0 0 0 
 Mean 18.6740 1.29 17.8387 7.6129 
Std. Deviation 6.60212 1.663 5.89858 1.33496 
Minimum 10.71 0 5.00 5.00 
Maximum 43.00 7 30.00 12.00 
Percentiles 25 13.6300 .00 14.7500 7.0000 
50 16.7300 1.00 20.0000 8.0000 
75 22.2200 2.00 22.0000 8.0000 
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Fig.25, Box Plot Showing Median Value Of Schirmer I among two groups 
                    (anti SSA positive and anti SSA negative group) 
 
 
In the box plot shown above in Figure 25 median value of Schirmer I test seen in 
anti SSA positive group is around 15mm± 5.7mm with a range of 5mm to 25mm. 
The median value seen in anti SSA negative group which is around 17.8 mm± 
5.8mm with a range of 5mm to 30mm. 
The sensitivity and specificity of Schirmer I test is 46.7% and 75.8%, with a 
positive likehood ratio of 1.92. 
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Fig.26, Box Plot Showing Median Value of TBUT among two groups 
( anti SSA positive and anti SSA negative group) 
 
In the box plot shown above in Figure 26 median value of TBUT test seen in anti 
SSA positive group is around 7.1secs ± 1.2 secs with a range of 6secs to 10 secs. 
The median value seen in anti SSA negative group which is around 7.6 
secs±1.3sec with a range of  5 secs to 12 secs. However 2 patients have a very low 
TBUT score of around 4 secs in this group and 5 patients have a higher value for TBUT 
in this group. 
The sensitivity and specificity of TBUT test is 63.3% and 51.6%, with a positive 
likehood ratio of 1.31. 
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Fig.27, Box Plot Showing Median Value of OSS among two groups 
(anti SSA positive and anti SSA negative group) 
 
In the box plot shown above in Figure 27 median value of OSS seen in anti SSA 
positive group is around 1.7 ± 1.7 with a range of 0 to 4. 
The median value seen in anti SSA negative group which is around 1.2 ±1.6 with 
a range of 0 to 7. However 3 patients have a very high OSS score of around 6 in this 
group. 
The sensitivity and specificity of OSS is 40% and 79%, with a positive likehood 
ratio of 1.90. 
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Fig.28, Box Plot Showing Median Value of OSDI among two groups 
( anti SSA positive and anti SSA negative group) 
In the box plot shown above in Figure 28  median value of OSDI score seen in 
anti SSA positive group is around 23.2 ± 8.8 with a range of 10.7 to 43.5. 
The median value seen in anti SSA negative group which is around 18.6 ±6.6 
with a range of 10.7 to 43.  However only 1 patient has an OSDI score of around 40 in 
this group. 
The sensitivity and specificity of OSS is 60% and 60.3%, with a positive 
likehood ratio of 1.51. 
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Corelation of anti-SSB : 
Corelation of anti SSB with Schirmer I test, TBUT and OSS suggests a positive likehood 
ratio of 1.72, 1.52 and 1.43 respectively as shown in table below 
Table 17, Corelation of anti SSB with Schirmer I test, TBUT and OSS 
 Sensitivity(%) Specificity(%) PPV(%) +LR 
OSDI 72.73 55.95 17.78 1.65 
Schirmer I 54.5 68.4 33.3 1.72 
TBUT 72.7 52.6 30.8 1.52 
OSS 45.5 68.4 18.8 1.43 
 
Table 18, Corelation of anti SSB with Schirmer I test, TBUT and OSS 
Statistics 
ANTI SSB 
OCULAR 
SURFACE 
DISEASE INDEX 
max_oss lsch ltbut 
positive N Valid 11 11 11 11 
Missing 0 0 0 0 
 Mean 23.9527 1.82 13.0000 6.7273 
Std. Deviation 10.22217 1.779 5.56776 .90453 
Minimum 10.71 0 5.00 6.00 
Maximum 43.50 4 20.00 8.00 
Percentiles 25 16.5000 .00 9.0000 6.0000 
50 22.2200 1.00 10.0000 6.0000 
75 31.3500 4.00 20.0000 8.0000 
negative N Valid 38 38 38 38 
Missing 0 0 0 0 
 Mean 20.4721 1.58 17.5000 7.6579 
Std. Deviation 7.32232 1.855 5.82516 1.49370 
Minimum 11.11 0 5.00 5.00 
Maximum 43.00 7 28.00 12.00 
Percentiles 25 15.1225 .00 12.0000 7.0000 
50 18.4000 1.00 18.0000 8.0000 
75 25.0000 3.00 22.0000 8.2500 
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Fig.29, Box Plot Showing Median Value of Schirmer I among two groups 
(anti SSB positive and anti SSB negative group) 
 
In the box plot shown above in Figure 29 median value of Schirmer I test seen in 
anti SSB positive group is around 13mm± 5.5mm with a range of 5mm to 20mm. 
The median value seen in anti SSB negative group which is around 17.5 mm± 
5.8mm with a range of 5mm to 28mm. 
The sensitivity and specificity of Schirmer I test is 54.5% and 68.4%, with a 
positive likehood ratio of 1.72. 
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Fig.30,  Box Plot Showing Median Value of TBUT among two groups 
(anti SSB positive and anti SSB negative group) 
In the box plot shown above in Figure 30 median value of TBUT test seen in anti 
SSB positive group is around 6.7secs ± 0.9 secs with a range of 6secs to 8 secs. 
The median value seen in anti SSB negative group which is around 7.6 
secs±1.4sec with a range of 5 secs to 12 secs. However 2 patients have a very low TBUT 
score of around 4 secs in this group and 4 patients have a higher value(>10secs) for 
TBUT in this group. 
The sensitivity and specificity of TBUT test is 72.7% and 52.6%, with a positive 
likehood ratio of 1.52. 
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Fig.31, Box Plot Showing Median Value of OSS among two groups 
(anti SSB positive and anti SSB negative group) 
 
In the box plot shown above in Figure 31 ,median value of OSS seen in anti SSB 
positive group is around 1.82 ± 1.7 with a range of 0 to 4. 
The median value seen in anti SSB negative group which is around 1.5 ±1.8 with 
a range of 0 to 7. However 3 patients have a very high OSS score of around 6 in this 
group. 
The sensitivity and specificity of OSS is 45.5% and 68.4%, with a positive 
likehood ratio of 1.43. 
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Fig.32, Box Plot Showing Median Value of OSDI among two groups 
(anti SSB positive and anti SSB negative group) 
 
In the box plot shown above in Figure 32  median value of OSDI score seen in 
anti SSB positive group is around 23.9 ± 10.2 with a range of 10.7 to 43.5. 
The median value seen in anti SSB negative group which is around 20.46 ±7.3 
with a range of 11.11 to 43.  However only 1 patient has an OSDI score of around 40 in 
this group. 
The sensitivity and specificity of OSS is 72.73% and 55.95%, with a positive 
likehood ratio of 1.65. 
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CORELATION BETWEEN LABIAL BIOPSY AND OSDI, SCHIRMER, TBUT, 
OSS  
The corelation of labial biopsy with Schirmer I, TBUT and OSS suggest a likelihood 
ratio of 3.38,1.80 and 4.89 as shown in table below 
Table 19, The corelation of labial biopsy with Schirmer I, TBUT and OSS 
 Sensitivity(%) Specificity(%) PPV(%) +LR 
OSDI 70.27 67.24 57.78 2.15 
Schirmer I 54.1 84.2 69 3.38 
TBUT 73 59.6 54 1.80 
OSS 51.4 89.5 76.0 4.89 
 
Table 20, The corelation of labial biopsy with Schirmer I, TBUT and OSS 
LABIAL BIOPSY OCULAR SURFACE 
DISEASE INDEX 
max_oss lsch ltbut 
Positive N Valid 37 37 37 37 
Missing 0 0 0 0 
 
Mean 24.1586 2.22 13.9730 6.8919 
Minimum 10.71 0 5.00 5.00 
Maximum 43.50 7 25.00 10.00 
Percentiles 25 16.6650 1.00 10.0000 6.0000 
50 22.2200 3.00 14.0000 7.0000 
75 31.2500 3.50 20.0000 8.0000 
 
Std. Deviation 9.00369 1.797 5.57019 1.14949 
Negative N Valid 57 57 57 57 
Missing 0 0 0 0 
 
Mean 17.4844 .82 19.1053 7.8596 
Minimum 11.10 0 8.00 5.00 
Maximum 35.55 6 30.00 12.00 
Percentiles 25 13.6150 .00 15.0000 7.0000 
50 16.6000 .00 20.0000 8.0000 
75 20.0000 1.00 22.0000 8.0000 
 
Std. Deviation 5.10798 1.255 5.30729 1.27389 
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Fig.33 and 34, Box Plot Showing Median Value of TBUT and Schirmer I 
respectively among two groups 
(labial biopsy positive and labial biopsy negative group) 
 In the box plot shown above in Figure 34, median value of Schirmer I test seen 
in biopsy positive group is around 13.9mm± 5mm with a range of 5mm to 25mm. The 
median value seen in labial biopsy negative group which is around 19.1 mm± 8mm with 
a range of 8 mm to 30mm. The sensitivity and specificity of Schirmer I test is 54.1% and 
84.2%, with a positive likehood ratio of 3.38. 
In the box plot shown above in Figure 33, median value of TBUT test seen in 
biopsy positive group is around 6.8secs ± 0.9 secs with a range of 5secs to 10 secs. The 
median value seen in biopsy negative group which is around 7.8 secs±1.4sec with a 
range of 5 secs to 12 secs. However 1 patients have a very low TBUT score of around 4 
secs in this group and 5 patients have a higher value(>10secs) for TBUT in this group. 
The sensitivity and specificity of TBUT test is 73% and 59.6%, with a positive likehood 
ratio of 1.80.  
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Fig.35 and 36, Box Plot Showing Median Value of OSS and OSDI respectively 
among two groups 
(labial biopsy positive and labial biopsy negative group) 
In the box plot shown above in Figure 35 ,median value of OSS seen in biopsy  
positive group is around 2.22  with a range of 0 to 7. The median value seen in biopsy 
negative group which is around 0.82 with a range of 0 to 6. However 6 patients have a 
very high OSS score of around 6 in this group. The sensitivity and specificity of OSS is 
51.4% and 89.5%, with a positive likehood ratio of 4.89.  
In the box plot shown above in Figure 36  median value of OSDI score seen in 
biopsy positive group is around 24.15 with a range of 10.7 to 43.5. The median value 
seen in biopsy negative group which is around 17.48 with a range of 11.11 to 35.5.  
However only 1 patient has an OSDI score of around 40 in this group. The sensitivity 
and specificity of OSS is 70.27% and 67.24%, with a positive likehood ratio of 2.15. 
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DISCUSSION 
 
 
Many of the autoimmune diseases, especially Sjogren‘s syndrome presents with 
complaints of dry eye. The ocular surface, forms an integrated part of diagnostic 
algorithms, either as a part of questionnaires or as objective tests, such as Schirmer test I, 
Schirmer test II, TBUT, vital dye such as  Rose bengal score (RBS), fluorescein and 
lissamine, ocular staining score (OSS).  
Inspite of knowing the importance of proper usage of these diagnostic tests in our 
clinical decisions, many tests have still not been subjected for precise evaluation, in order 
to determine their clinical effectiveness in diagnosing the disease. 
In our study, the incidence of primary Sjogren‘s syndrome was 32.63%             
(31 patients). 
 94.7% of the patients were female and most (56.8%) of the patients were in the 
age group of 41-60 years suggesting that the disease is more common among females 
and peak incidence is in 4
th
 to 5
th
 decade as seen in previous studies(3). 
Ocular symptoms can be exaggerated by the decrease in humidity that exists in 
air-conditioning environment, dry weather and exposure to smoke of cigarette. The dry 
eye symptoms were not associated with the occupation of the patient, as most of the 
female patients (66 patients) were housewives and very few (3 patients) were working 
with air conditioner in their office out of which 2 of them were in SS group, but the 
difference is not statistically significant. Thereby in this study, the symptoms cannot be 
associated with the surrounding environmental condition. 
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Ocular complaints: 
Ocular complaints were seen in most (90.5%) of the patients in our study and that 
may be the reason for the clinical suspicion of Sjogren‘s syndrome. The mean duration 
of symptoms was 2.15 years with a minimum of 1 month and maximum of 96 months. 
There was no difference in the duration of symptoms between male and female patients. 
The most common ocular complaints seen were itching and foreign body sensation 
(56.8% patients). Objective tests of dry eye (like Schirmer I, TBUT, OSS) in these 
symptomatic patients with complaints of itching and foreign body sensation, did not 
show statistically significant difference between SS and Non SS group (p>0.05). 
The other ocular complaints like irritation, redness, stickiness, photophobia, gritty 
sensation, intolerance to CL, visual disturbance and swelling over cheek (parotid 
enlargement) had a varied distribution in between two groups. 
Visual acuity of most of the patients (85.26%) was 6/6 and only 2 patients of age 
group 50-60 years have decreased vision that may be due to age related cataract. 
 
Anti- SSA /anti- SSB: 
Many studies(36) found the association of anti SSA and anti SSB with the 
diagnosis of pSS. Study conducted by Hammi et al(32) found that anti SSA/Ro and anti 
SSB/La antibodies in serum were more useful than in saliva for diagnosing the 
disease(p=0.001). Hansen et al(72) conducted a study in103 patients of pSS diagnosed 
by Copenhagen criteria and proposed that 67% were positive for anti SSB and 71% 
patients were positive for anti SSA. They also concluded that in his study all anti SSB 
positive patients had anti SSA also. Toker et al(34) found the association of these 
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antibodies with the severity of the disease and also noted that the  percentage of patients 
who were positive for anti SSA were more than for anti SSB as seen in our study. 
Jacobson et al(56) found increased level of anti SSA and anti SSB in patients with 
symptoms of dry eye but difference was not significant. 
In our study anti SSA was positive in 23 patients and anti SSB was positive in 11 
patients who were diagnosed to have pSS. So in our study there is good association 
between anti SSA and diagnosis of pSS (sensitivity of 76.7% and specificity of 88.7% 
positive predictive value of 76.7%, +LR of 6.78). 
The sensitivity of anti SSB was found to be poor (52.4%) but good specificity 
(73.7%). The positive likelihood ratio was found to be 1.99. Most (72.7%) of the patients 
who were positive for anti SSB were also positive for anti SSA which is in line with 
other studies.(34) It can account that anti SSA test is feasible and can be done alone as a 
diagnostic test to make it affordable. 
 
Labial biopsy: 
Minor salivary is considered to be the ‗gold standard‘ in diagnosing primary 
Sjogren‘s syndrome. Nakamura et al (36)(73) conducted a retrospective study and 
found an association between minor salivary gland biopsy and the diagnosis of pSS 
(odds ratio 105;95% CI 13, 849). Yazisiz et al (74)concluded that MSGB has the best 
predictive value for diagnosis of pSS with highest sensitivity and specificity(p<0.001). 
Guellec et al (37) failed to found the association between MSGB and the disease.  
Our study found a good association of MSGB with the diagnosis of the disease 
(sensitivity of 96.8% and specificity of 88.9% and Positive predictive value of 81.1%, + 
LR of 8.72).  
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Depending on the attitudes of individual researchers, labial biopsy is indicated if 
there is suspicion in final diagnosis based on clinical symptoms. However, it is important 
to note that the biopsy has a wider clinical utility, because it can be detected and other 
diseases, such as the sarcoidosis. 
Diagnostic criteria: 
We found 31 patients diagnosed of pSS in our study on the basis of ACR criteria 
(6),in which the patients who were positive for OSS score were also considered. Most of 
them fall into the diagnostic criteria as they have anti SSA positive and labial biopsy 
positive. We had an added advantage of not including the patients on the basis of AECG 
criteria(47) which takes into account the subjective symptoms and misclassify most of 
the symptomatic patients as seen in other studies(2) but the inclusion of OSS score in 
ACR criteria becomes the limitation of our study. 
In the American-European Community (AECG) criteria, positive objective ocular 
signs includes positive test result of Schirmer I or positive Rose Bengal staining 
(RBS)(75). Most of the studies recruit the patients as Sjogren‘s syndrome, based on the 
results of these tests making a major limitation of incorporation bias. In our study 
patients were recruited on the basis of ACR criteria(6) which does not include Sch-I.  
 
OSDI score 
OSDI score of severe (36) was seen in 3 patients and all 3 were having pSS but 
this could not account for good predictive value as the high score was seen in very small 
portion of the study group. Most of the patients (64.5%) were in range of mild to 
moderate OSDI score (18-36). This distribution suggest that most patients of pSS were 
having mild to moderate symptoms thereby making OSDI as one of the useful diagnostic 
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tool. Few patients (25%) were having OSDI in normal range which can be explained 
either due to reduced severity of the disease or due to use of lubricants.  
OSDI has a moderate performance in diagnosing the disease (sensitivity of 71%, 
specificity of 65%, p<0.001) with the median value seen in the disease group (pSS) as 
24.60± 9.36 with area under curve of 0.718 and a positive likelihood ratio of 2.02.  
OSDI score used in many research(9)(61)(76), showed high specificity and a 
relative diagnostic features  used by clinician for diagnosis of pSS. 
Schiffman et al (9) concluded that OSDI has good sensitivity and specificity 
which is effective in discriminating normal and various grades of dry eyes as defined by 
physician‘s evaluation of severity and a composite disease severity score. 
Vitale et al (53) found a modest association between objective measures of dry 
eye and questionnaire of VT-HRQ, whereas NEI-VFQ and OSDI was found to have 
similar impact of SS-related dry eye on VT-HRQ. 
As the process of collecting information related to patient‘s ocular complaint is 
tedious due to heterogenicity of symptoms. In this study we included OSDI questionnaire 
as it is fast in evaluating symptoms and later it can also be used for comparison of same 
symptoms over time or after therapy. Although it has been described in studies that 
ocular surface damage may not always be associated with symptoms.  
But in our study 74% patients were found to have a score of 18 or more 
suggesting its association with the disease damage, but 45% of the Non SS group was 
also found to have a score of 18 or more which can be due to age related dry eye or some 
other pathology.  The average score found in our study in pSS group was 24.6. One 
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possibility of difference in our result in comparison to Vitale(53) may be the stoppage of 
lubricant in our study one day prior to test. 
Schirmer I test: 
The utility and diagnostic efficacy of Schirmer I is still a topic of debate. Vitali et 
al(75),  demonstrated that Schirmer test  is one of the reliable test for diagnosis of SS 
which shows a balance between sensitivity and specificity, which is also supported by 
the study of Hay et al(1) who found a good sensitivity and specificity of Schirmer test in 
hospital setting against the clinician ‗gold standard‘ diagnosis of Sjogren‘s syndrome. 
Whitcher et al(7) showed a significant difference in test results of Schirmer test in SS-
KCS and KCS only group. But some of the studies(77)(64) revealed that Schirmer test 
has poor diagnostic accuracy and there is a weak correlation between the tests results and 
patients symptoms (63). 
The most widely contained opinion is that Schirmer test is not very reliable test 
and have a poor reproducibility(55) (78)(79)(80)which vary at every visit. And it is also 
shown to have less diagnostic value(1) in mild to moderate dry eyes, but a very low 
Schirmer I value can be considered as a good indicator of aqueous deficient tear film.  
Schirmer I value of ≤ 5mm/5min was the cut off mentioned in AECG criteria for 
pSS in many studies(62)(61). In our study only 9.67% of the pSS group has a Schirmer 
value ≤ 5 with a very low sensitivity (19.4%) and high specificity (96.9%). If we use this 
as a limit value then this would significantly diminishes its clinical importance and will 
give a high false negative result. In this study, as projected in other similar studies, more 
than 50% of the patients showed negative results for Sch-I (77)(78) and if the cut off 
value of the test is not raised, differential diagnostic performance of the same will 
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remains relatively weak. Therefore, the mean value of tear secretion is higher than the 
pathological threshold (≤ 5mm /5mins) between 2 groups.  
In our study cut off value for Schirmer I is more than reference range with ≤ 
15mm (sensitivity of 64.5% and specificity 85.90%).The likelihood ratio is high (4.57) 
with ROC curve showing the large area under the curve (0.779) which is almost equal to 
the AUC of TBUT (0.780), thereby making both Sch I and TBUT equally effective in 
diagnosing the disease. No significant differences between ROC curves of TBUT test 
and Sch-I tests (p<0.001). Schirmer I (done without use of local anesthesia) alone, act as 
a relative single diagnostic test for viewing the effect of staging of the disease and effect 
of therapy on the test score. 
So in our study Schirmer I has better diagnostic performance than OSS in an 
Indian population, since there is statistically significant difference between two group of 
patients (p<0.001, Mann whitney, 94). Findings in this study are in mild discrepancy 
with other similar research.    
Mean values of Schirmer I test in patients with pSS group amounted to 12.77 
mm± 5.37, and in patients with Non SS group is 19.21 mm ± 4.97. 
 
TBUT test values 
In our study, for TBUT ≤ 10secs, sensitivity was high (96.8%) but specificity was 
low (12.5 %) which means that if the test is negative the possibility of having disease 
cannot be excluded as seen in other studies(66). Most commonly described marginal 
TBUT test value is 10 sec in many studies.  
TBUT depicting a limit value of 8 secs was found to have a balance of sensitivity 
(80.6%) and specificity (60.90%) in our study, which is in line with other studies(80). 
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There was a statistically significant difference (p<0.001) seen in TBUT value between 
two groups. Mean TBUT in patients with pSS group is 6.6±1.04 sec and in Non SS 
group is 7.87±1.24 sec. The role of TBUT in diagnosis of pSS is shown by ROC curve 
which is shifted towards upper left corner and area under the curve is 0.780 which is 
almost same as that of Schirmer I (0.779), thereby having equally good efficacy in 
diagnosing the disease. The standard error seen was 0.052 with 95% confidence interval 
of 0.679 -0.881. 
We found good diagnostic performance of TBUT (+LR of 2.06) in our population 
with statistically significant difference between the two groups (p<0.001). 
 
OSS score 
In our study, for OSS of 3 or more, sensitivity is high (90.60%) with average 
specificity (61.3%) It is the most common limit range value seen in other studies and 
also in ACR criteria ((6)(68). There was a statistically significant difference (p<0.001) 
seen in OSS value between the two groups. Mean OSS in patients with pSS group is 
2.48±1.84 sec and in Non SS group is 0.84±1.19 sec. The role of OSS in diagnosis of 
pSS is shown by ROC curve which is shifted towards upper left corner with area under 
the curve is 0.766 and positive likelihood ratio of 2.34 which is less than that of Schirmer 
I and TBUT. We found an average diagnostic performance of OSS in our population 
with statistically significant difference between the two groups (p<0.001). 
Whitcher et al(68) found that among participant with KCS only, median OSS 
(Ocular staining score) was 5 compared to 9 among those with SS-KCS with statistically 
significant difference between 2 subgroups (p<0.0001). This study also showed 
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significant difference in Schirmer I and TBUT among 2 subgroups with no difference in 
symptoms of dry eye or dry mouth. 
Corelation between subjective symptoms by (OSS score) and SchirmerI,TBUT and 
OSS 
In our study, OSDI shows a moderate correlation with other tests such as 
Schirmer I, TBUT and OSS which is in line with other studies(49).This moderate 
correlation can be because of heterogenous group of patients with dry eyes, these 
measures do not have sufficient sensitivity to assess the complete range of dry eye 
abnormalities. And in some patients, these measures may correlate closely to patient 
perception of disease severity. Therefore OSDI is unique in quantitative assessment of 
both frequency of dry eye symptoms and impact of these on the vision related 
functioning. It also has required psychometric ability to be used as an end point for 
clinical trials of dry eye disease. 
Hay et al (1) found no association was seen between antibody to SSA or SSB 
and either symptoms or signs of dry eyes or dry mouth. Strongest association was seen in 
subjects with both ocular and oral symptoms and objective tests. He concluded a weak 
association between the presence of oral or ocular symptoms and test results of USF 
(unstimulated salivary flow) or Schirmer I. They analysed the association separately for 
subjects less than and over 55 years of age and found a higher frequencies of abnormal 
findings in the elderly. It was due to age related changes causing dysfunction of lacrimal 
and salivary glands. Ocular symptom in elderly was assumed to be probably due to other 
causes like blepharitis thereby not giving an abnormal Schirmer test.  
Barboza et al (63) showed a weak correlation between the symptoms of patients 
with Sjögren's syndrome and ocular signs that indicate disease severity concluding that 
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all symptomatic patients did not showed positivity for corresponding tests. This weak 
correlation was attributed to variation in corneal sensitivity. 
Nichols et al (65)  found a poor correlation between symptoms of dry eyes and 
their tests after adjustment for age and use of lubricants which was also in support of 
whitcher study (68). 
In our studies there is a positive correlation seen between subjective symptoms as 
depicted by OSDI score and subjective test of Schirmer I, TBUT and OSS score 
respectively (p value of 0.001, 0.001 and 0.005 respectively).There is a positive 
correlation seen in between OSDI and OSS (R=+0.285) and a negative correlation of 
OSDI with Schirmer I and TBUT (R= -.397, R= -.341).  
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CONCLUSION 
 
 Primary Sjogren‘s syndrome is more common in females, with peak incidence 
seen in 4
th
 to 5
th
 decade. 
 The commonest ocular complaints seen in this study, in patients with pSS were 
itching and foreign body sensation. Visual disturbance was rare in our study 
population. 
 The mean duration of symptoms was 2.15 years. 
 There is a good likelihood of diagnosing pSS with anti SSA than with anti SSB, 
but biopsy holds the strongest association with the disease (+LR; 8.72). Since it is 
an invasive method, the results of our study indicate the possibility of performing 
noninvasive tests in differential diagnosis of pSS, such as Schirmer I, TBUT and 
OSS, which have good statistical parameters and thereby in future may lead to 
simplification of the diagnostic protocol for pSS.  
 ACR criteria selected in our study for recruitment of patients avoid the 
misclassification of symptomatic patients as seen in AECG criteria which include 
subjective symptoms. 
 In our study Schirmer I, TBUT, OSS and OSDI scores were statistically worse in 
patients with pSS compared with patients with Non-SS group. 
 Our study shows that if we assume the cut off range of Schirmer I ≤ 5mm/5mins 
and TBUT ≤ 10 secs, the clinical importance of the tests is decreased and rate of 
false negatives increases.  
 Our study indicates that the cut off value of Schirmer I ≤ 15mm/5mins, TBUT ≤ 
8 secs and OSS score ≥ 3 may  offer better diagnostic yield for diagnosing pSS in  
Indian population. 
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 Schirmer I was found to have better diagnostic performance with highest 
likelihood ratio (4.52) than TBUT and OSS (+ LR for TBUT and OSS was 2.06 
and 2.34 respectively). So in Indian population, Schirmer I still holds its 
significance as the test of choice for diagnosis of pSS.  
 There is good correlation of symptoms as depicted by OSDI score, with tests like 
Schirmer I, TBUT and OSS score with p<0.001.  
 Ophthalmic examination aids to answer to the question, whether patient has 
Sjogren's syndrome or not, if the above tests are performed properly and 
understood as to what each of these represent.  
 The results of our present study support an increased index of suspicion for dry 
eye and the possibility of pSS should be considered in all patients with clinically 
significant dry eyes. 
 Sjogren‘s syndrome leads to slow and progressive impairment of exocrine gland 
specially salivary and lacrimal gland function. Therefore it is imperative to   
perform dry eye tests for early recognition, timely management and monitor 
response to treatment.  
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LIMITATION 
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LIMITATION 
 
 It is assumed that a significant part of pSS patients included in our study have 
met the ocular sign criteria of ACR, therefore introducing incorporation bias. 
 The results of the objective tests (Schirmer I, TBUT and OSS) used in our study 
may be influenced by the stage of the disease and/or by the therapy. 
 Although in our study with the sample size of 95 patients, we were able to 
correlate the ocular symptoms with dry eye tests, we need to demonstrate this in a 
larger population. 
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APPENDIX B 
INFORMATION SHEET 
 
Title: Diagnostic performance of dry eye tests in Primary Sjogren‘s Syndrome in an 
Indian setting. 
 
You are invited to take part in this study. The information in this document is meant to 
help you decide whether or not to take part in the study. Please feel free to ask if you 
have any queries or concerns. 
 
What is the study about? Sjögren syndrome is an immunological disease in which your 
body‘s immune cells attack and destroy the glands that produces tears and saliva leading 
to dry eye and dry mouth. It can also affect other organs including lungs, kidneys, skin 
and the nervous system. Eye symptoms are related to decreased tear secretion.  Patients 
sometimes may not be troubled until symptoms start affecting their daily activities 
leading to a poor quality of life. 
 
It can occur in two forms: Primary Sjogren syndrome, in which there are symptoms of 
dry eye and mouth and Secondary Sjogren Syndrome, where it is associated with other 
disorder like Rheumatoid Arthritis, Systemic Lupus Erythematosis etc .Early recognition 
of Sjogren syndrome may prevent complication such as corneal ulceration, dental caries, 
chronic mouth infection and development of serious illnesses like vasculitis, peripheral 
neuropathy, renal and pulmonary involvement. 
 
However, there is no straightforward and simple diagnostic test for Sjogrens syndrome 
.The diagnosis depends on clinical signs and symptoms, pathological findings of lower 
lip biopsy, or the presence of anti SSA and/or anti SSB antibodies in the blood. The tear 
secretion in the eye can be measured by various tests. They are Schirmer I, Tear Break-
up time, Ocular surface staining score. This helps in early recognition of Sjogrens 
syndrome in a way which is simple, inexpensive, non invasive and easily available so 
that early treatment plan can be made.  
 
If you take part, what will you have to do? 
If you take part in the study, an appointment will be arranged for you to have an eye 
check up in the Outpatient clinic of the Eye Department. You will have to spend about 
two to three hours in the department. A routine eye examination will be performed. You 
will not be required to come for any follow up visits for the purpose of this study. 
 
Are there any risks for you if you take part in the study? 
Participation in the study only involves undergoing a routine eye check up. We do not 
expect any injury to happen to you, but if you do develop any side effects or problems 
due to the study, these will be treated at no cost to you. However, we are unable to 
provide any monetary compensation. 
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Do you have to pay? 
As participation in the study involves a routine eye check up in the Outpatient clinic of 
the Eye department, you will have to pay for a General OPD appointment. 
 
What are the benefits to you if you take part in the study? 
As a patient with Primary Sjogren‘s Syndrome, you are at increased risk of developing 
dry eye and its complication. If you participate in the study, 
1. You will be screened for dry eye, which if detected and treated promptly, can prevent 
serious ocular complications like corneal scarring, infection, ulceration and loss of 
vision.  
2. You will be counseled regarding the symptoms of dry eye and preventive measures. 
3. You will also be able to have a general eye check up and treatment for other unrelated 
eye problems that you may have. 
 
What are the possible benefits to other people? 
The results of the research may provide benefits to the society in terms of advancement 
of medical knowledge and to help in diagnosing the disease with simple tests. 
 
Can you decide not to participate? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way. Your doctor will still take care of you and 
you will not lose any benefits to which you are entitled. 
 
Will your personal details be kept confidential? 
The results of this study may be published in a medical journal, but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission, should you decide to participate in this study. 
 
If you have any further questions, please ask Dr. Roma Johri or Dr. Jayanthi Peter 
(Tel: 0416 2281201) or email: roma_johri@yahoo.co.in 
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CONSENT FORM 
 
Study Title-   DIAGNOSTIC PERFORMANCE OF DRY EYE TESTS IN 
PRIMARY SJOGREN SYNDROME PATIENT IN AN INDIAN SETTING 
 
Study Number: 
Subject’s Initials:  
Subject’s Name:  
 
Please put your signature here 
(Subject) 
 
 
 
i I confirm that I have read and understood the information sheet dated   for the 
above study and have had the opportunity to ask questions.  
ii. I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
iii. I understand that the Sponsor of the clinical trial, others working on the 
Sponsor‘s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published.  
iv. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s)  
v. I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:       
Date:  
Signatory‘s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: Study Investigator‘s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: 
Name of the Witness: _____________________________ 
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                   రోగి సభాచాయ ఩త్రభు 
 
శీరిషక: భాయత్ నే఩ధయంలో ప్఺ర థమిక జగరనె్సస స఻ండ్రరమ్ లో పొ్ డి్ కనఽన ఩రీక్షల రోగనిర఺ధ యణ ఖచ్చిత్త్వం . 
 
మీయు ఈ అధయమనంలో ప్఺లగొ నడ్ానికి ఆహ్వవనిత్ేలు. ఈ ఩త్రంలోని సభాచాయం మీయు ఈ 
అధయమనంలో ప్఺లగొ నడ్ానికి నియణమం తీసఽకోవడ్ానికి సహ్వమం చేసఽత ంది.మీకు ఏ యకమ ైన ఩రశ్నలు 
లేదా సభసయలు ఉంటే సంకోచ్చంచకండ అడగండి్. 
 
దేని గురించ్చ అధయమనం ? 
జగరనె్సస స఻ండ్రరమ్ అనేది ఒక యకమ ైన రోగనిరోధక వ్఺యధి, ఇందఽలో మీ శ్రీయం యొకక వ్఺యధి నిరోధక 
కణాలు కన్ననళ్ైు  భరిము లాలాజలభు ఉత్఩త్తత  చేసే గంెథఽల఩ ై దాడి్ చేస఻ కళ్ైు  భరిము నోయు 
పొ్ డి్ఫారేల చేసఽత ంది. ఇది ఊ఩఻రిత్తత్ేత లు, కిడ్న లు , చయమం,నాడ్న వయవసథ భరిము ఇత్య 
అవమవ్఺లనఽ ఩రభావిత్ం చేమవచఽి. కళ్ుకు సంఫంధించ్చ కన్ననటి ఊటనఽ త్గిొసఽత ంది. కొనినస఺యుు  ఈ 
వ్఺యధి ఫారిన ఩డి్న రోగులు, వ్఺యధి లక్షణాలు వ్఺రి దినందిక జీవిత్ం మీద ఩రఫావం చఽప్఺నంత్వయకు 
ఇఫబంది ఩డయు. 
  
ఇది రరండె యౄప్఺లోు  సంబవించవచఽి : ప్఺ర థమిక జగరనె్సస స఻ండ్రరమ్: దీని లక్షణాలు కనఽన భరిము 
నోయు పొ్ డి్ఫాయటం.రరండ్ర  జగరనె్సస స఻ండ్రరమ్: యుభటాయడ్ ఆయథరరైటిస్ , స఻సటమిక్ లు఩ుస్ ఎయత్తభాటోస఻స్ 
వంటి ఇత్య యుగమత్లతో కలస఻ ఉంట ంది. జగరనె్సస స఻ండ్రరమ్ నఽ భుందఽగ గురితంచడం వలన వుకు 
వరణోత్఩త్తత  , దంత్ క్షమం , దీయఘక఺యౌక నోటి వ్఺యధి భరిము వ్఺సఽకల ైటిసలు  , నర఺ల వ్఺యధి, 
భూత్ర఩఻ండ్ాల వ్఺యధఽల వంటి తీవరమ ైన సభసయలనఽ నిరోధించవచఽి. 
 
అయతే , జగరనె్సస స఻ండ్రరమ్ నఽ గురితంచడ్ానికి సరి అయన రోగనిర఺ధ యణ ఩రీక్షలు లేవు. కంటి లో 
కన్ననటి స఺ర వం వివిధ ఩రీక్షల దావర఺ కనఽకోకవచఽి. అవి టిమర్ విడి్ప్ల వడ్ానికి సభమం , 
఩రత్యక్షమ ైన ఉ఩రిత్ల యంజనం సల కయు. ఇవి జగరనె్సస స఻ండ్రరమ్ నఽ గురితంచడ్ానికి చవకరైన భరిము 
సఽలబమ ైన ఩దదత్ేలు, వీటితో భుందసఽత  చ్చకిత్స ఩రణాళికనఽ త్మాయు చేమవచఽి. 
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మీయు ప్఺లగొ ంటే, మీయు ఏమి చేమాయౌస ఉంట ంది ? 
మీయు అధయమనంలో ప్఺లగొ ంటే, ఆసఽ఩త్తరలో కంటి విభాగంలో కళ్ు  ఩రీక్షల కోసం అప్఺యంట్మంట్ 
ఏర఺఩ట  చేమఫడెత్ేంది. మీయు ఈ విభాగంలో రరండె లేదా భూడె గంటల సభమం ఉండ్ాయౌస 
ఉంట ంది. మీకు ఒక స఺ధాయణ కంటి ఩రీక్ష చేమఫడెత్ేంది. మీయు ఈ అధయమనం కోసం భయల 
ర఺వ్఺యౌసన అవసయం ఉండదఽ. 
 
మీయు అధయమనంలో ప్఺లగొ ంటే ఎమ ైన సభసయలు ఉంటామా ? 
ఈ  అధయమనంలో మీకు ఒక స఺ధాయణ కంటి ఩రీక్ష భాత్రమే చేమఫడెత్ేంది. మీకు ఎట వంటి హ్వని 
కలగదఽ, ఒకవే్ళ్ మీకు అధయమనం క఺యణంగ఺ ఏ దఽష్ప ర్భావ్఺లు లేదా సభసయలు వసేత , మీకు  
ఎట వంటి వయమం లేకుండ చ్చకిత్స చేమఫడెత్ేంది. అయతే, ఩రిహ్వయం కింద ధన యౄ఩ేన ఏది 
చెయౌుంచఫడదఽ. 
 
మీయు డఫుబ చెయౌుంచాయౌసన అవసయం ఉందా ? 
ఈ  అధయమనంలో ఆసఽ఩త్తరలో కంటి విభాగంలో కళ్ు  ఩రీక్ష చేమఫడెత్ేంది, మీయు స఺ధాయణ అవుట్ 
఩ేష ంట్ అప్఺యంట్మంట్ యుసఽభు చెయౌుంచాయౌస ఉంట ంది. 
 
మీయు ఈ అధయమనంలో ప్఺లగొ ంటే ఩రయోజనాలు ఏమిటి ? 
ప్఺ర థమిక జగరనె్సస స఻ండ్రరమ్ ఉనన రోగి, పొ్ డి్ కనఽన భరిము దాని వలు  వచేి ఇత్య సభసయల ఫారిన 
఩డే్ ఩రభాదం ఉంది. మీయు అధయమనంలో  ప్఺లగొ ంటే, 
1. మీకు పొ్ డి్ కనఽన ఩రీక్ష చేమఫడెత్ేంది, నిర఺ద యణ అయతే వ్ ంటనే చ్చకిత్స ఉంట ంది, దాని 
వలు  కంటి భచిలు , సంకభెణ , వరణోత్఩త్తత  భరిము దృష఻ట కోలో఩వడం వంటి తీవరమ ైన కంటి 
సభసయలు నిరోధించవచఽి. 
2. మీకు పొ్ డి్ కనఽన లక్షణాలు భరిము నివ్఺యణ చయయలకు సంఫంధించ్చ సలహ్వ 
ఇవవఫడెత్ేంది. 
3. మీకు స఺ధాయణ కంటి ఩రీక్ష చేమఫడెత్ేంది, మీకు ఉనన ఇత్య కంటి సభసయలకు చ్చకిత్స 
చేమఫడెత్ేంది. 
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ఇత్యులకు కయౌగే  ఩రయోజనాలు ఏమిటి? 
ఈ ఩రిశోధన పయౌతాలు సభాజానికి  వ్ ైదయ విజాా న అభివృదిద  ఩యంగ఺ భరిము స఺ధాయణ ఩రీక్షలు 
దావయ వ్఺యధి నిర఺ధ యణ చేమటానికి సహ్వమ ఩డతాయ. 
 
ఈ అధయమనంలో ప్఺లగొ ననఽ అని మీయు నియణమం తీసఽకొనగలర఺ ?  
ఈ అధయమనంలో మీ భాగస఺వభయం ఩ూరితగ఺ సవచఛందమ ైనది భరిము ఈ అధయమనంలో మీ 
భాగస఺వభయనిన ఉ఩సంహరించఽకోవ్఺డనికి మీకు అనిన విధాల అధిక఺యం ఉంది. ఒకవే్ళ్ మీయు 
ఉ఩సంహరించఽకుంటే, అది ఆసఽ఩త్తరలో మీ స఺ధాయణ చ్చకిత్సనఽ ఩రభావిత్ం చేమదఽ భరిము అనిన 
఩రయోజనాలకు మీయు అయుహ లు. 
 
మీ వయకితగత్ వివర఺లు గో఩యంగ఺ ఉంచఫడతామ ? 
ఈ అధయమనం యొకక పయౌతాలు వ్ ైదయ ఩త్తరకలో ఩రచఽరించఫడవచఽి, క఺ని మీ ఩ేయు ఏ ఩రచఽయణ లేదా 
఩రదయశనలో చేయిఫడదఽ. అయతే , మీ వ్ ైదయ పయౌతాలు మీ అదన఩ు అనఽభత్త లేకుండ్ా 
అధయమనంతో సంఫంధం ఉనన వయకుత లు సమీక్షిస఺త యు. 
 
మీయు ఏ ఇత్య ఩రశ్నలు ఉనన Dr. Roma Johri లేదా Dr. Jayanthi Peter (ఫల : 0416 2281201)  
లేదా  ఇమ యల్: roma_johri@yahoo.co.in అడగండి్. 
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ఆమోద ఩త్రభు 
శీరిషక: భాయత్ నే఩ధయంలో ప్఺ర థమిక జగరనె్సస స఻ండ్రరమ్ లో పొ్ డి్ కనఽన ఩రీక్షల రోగనిర఺ధ యణ ఖచ్చిత్త్వం. 
 
అధయమన సంఖయ: 
వయకిత ఩ూరిత ఩ేయు: 
ఇకకడ మీ సంత్కం చేమండి్: 
 
( విష్పమం ) 
 
i. నేనఽ ఩ ై అధయమన సభాచాయ ఩త్రభునఽ చదివి అయథం చేసఽకునాననఽ భరిము ఩రశ్నలు 
అడి్గ ేఅవక఺శ్ం కయౌగి ఉనాననఽ. 
ii. ఈ అధయమనంలో నా  భాగస఺వభయం ఩ూరితగ఺ సవచఛందమ ైనది భరిము ఏ సభమంలో 
ఆమన నేనఽ నా  భాగస఺వభయనిన నా వ్ ైదయ సంయక్షణ లేదా చటట఩యమ ైన హకుకలనఽ 
కోలో఩కుండ ఏ క఺యణం లేకుండ్ా ఉ఩సంహరించఽకోగలనఽ. 
iii. ఈ అధయమనంతో సంఫంధం ఉనన వయకుత లు నా  వ్ ైదయ పయౌతాలనఽ, నేనఽ నా 
భాగస఺వభయనినఉ఩సంహరించఽనన, నా  అదన఩ు అనఽభత్త లేకుండ్ా సమీక్షి జయ఩డ్ానికి 
ఒ఩ు఩కుంటృనాననఽ. క఺న్న, నా  ఩ేయు ఏ ఩రచఽయణ లేదా ఩రదయశనలో ఫహియొత్ం క఺క౅డదఽ. 
iv. ఈ అధయమనం నఽండి్ ఉత్఩ననభయయ  పయౌతాలు శ఺స఼తమీ ఩రయోజనల కోసం 
ఉ఩యోగించడ్ానికి అంగీకరిసఽత నాననఽ. 
v. నేనఽ ఩ ై అధయమనం ప్఺లగొ నడ్ానికి అంగీకరిసఽత నాననఽ. 
 
 
వయకిత /ఆమోదన్నమమ ైన ఩రత్తనిధి యొకక సంత్కం ( లేదా ఫొ టనవే్యౌ భుదర ) : 
తేదీ : 
సంత్కదాయుని ఩ేయు : _________________________________ 
఩రిశోధకుడి్ని సంత్కం : ________________________ 
విష్పమ ఩రిశోధకుడి్ ఩ేయు : _________________________ 
తేదీ : 
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స఺క్షి యొకక సంత్కం : ___________________________ 
స఺క్షి యొకక ఩ేయు : _____________________ 
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APPENDIX C 
PROFORMA 
DIAGNOSTIC PERFORMANCE OF DRY EYE TESTS IN PRIMARY 
SJOGREN’S SYNDROME PATIENT IN INDIAN SETTING 
 
SERIAL NUMBER: 
NAME:                                                                     AGE:                           SEX: M /F 
OCCUPATION:                                      CONTACT NO.: 
CMC HOSPITAL NO.:                                               SCHELL HOSPITAL NO:                                               
OCULAR SYMPTOMS:-- 
a. CHIEF COMPLAINTS :- 
b. DURATION OF SYMPTOMS: 
c. TREATMENT: 
d. DRUG HISTORY: 
e. OSDI: 
                                                             RIGHT EYE                                      LEFT EYE 
VISUAL ACUITY 
 
  
SCHIRMER‘S I (in mm) 
 
  
TBUT (in sec) 
 
  
CORNEAL FLUORESCEIN 
STAINING GRADE-OSS 1 
 
  
OCULAR SURFACE 
EXMINATION 
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CONJUNCTIVAL LISSAMINE 
STAINING GRADE—OSS II                         
 
  
 
TOTAL OCULAR STAINING 
SCORE 
  
 
INVESTIGATIONS: 
1. ANTI SSA 
2. ANTI SSB 
3. MINOR SALIVARY GLAND BIOPSY (DATE:                         ) 
 
 
4. OTHERS 
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APPENDIX D: 
                               SICCA Ocular staining score (OSS) 
                                     Right Eye                                                   Left Eye 
                   Lissamine green      Fluorescein            Lissamine green       Fluorescein 
                     (conjunctiva only)     (cornea only)                       (conjunctiva only)         (cornea only) 
    
  
 
 
 
 
  Extra points (fluorescein only): +1 for patch of confluent staining 
+1 for staining in papillary area 
+1 for Filaments 
Total score ranges from 3 to 12 per eye for assessment of severity of keratoconjunctivitis 
sicca 
 
 
 
 
 
 
 
Grades  Dots Grades Dots 
 0 0-9 0 0 
1 10-32 1 1-5 
2 33-100 2 6-30 
3 >100 3 >30 
Grades  Dots Grades Dots 
0 0-9 0 0 
1 10-32 1 1-5 
2 33-100 2 6-30 
3 >100 3 >30 
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APPENDIX E: OCULAR SURFACE DISEASE INDEX 
Circle the number in the box that best represents each answer 
HAVE YOU EXPERIENCED ANY OF THE FOLLOWING DURING THE LAST 
WEEK: 
  ALL OF 
THE 
TIME 
MOST 
OF THE 
TIME 
HALF 
OF THE 
TIME 
SOME 
OF THE 
TIME 
NONE 
OF THE 
TIME 
1. Eyes that are sensitive to light? 4 3 2 1 0 
2. Eyes that feel girtty? 4 3 2 1 0 
3. Painful or Sore eyes? 4 3 2 1 0 
4. Blurred vision? 4 3 2 1 0 
5. Poor vision? 4 3 2 1 0 
  Sub Total score fo ranswr 1 to 5  
 
HAVE PROBLEMS WITH YOUR EYES LIMITED YOU IN PERFORMING ANY OF 
THE FOLLOWING DURING THE LAST WEEK: 
  ALL OF 
THE 
TIME 
MOST 
OF THE 
TIME 
HALF 
OF THE 
TIME 
SOME 
OF THE 
TIME 
NONE 
OF THE 
TIME 
 
6. Reading? 4 3 2 1 0 N/A 
7. Driving at night? 4 3 2 1 0 N/A 
8. Working with computer 
or bank machine (ATM)? 
4 3 2 1 0 N/A 
9. Watching TV? 4 3 2 1 0 N/A 
  Sub Total score fo ranswr 1 to 5  
 
HAVE YOUR EYES FELT UNCOMFORTABLE IN ANY OF THE FOLLOWING 
SITUATION DURING THE LAST WEEK: 
  ALL OF 
THE 
TIME 
MOST 
OF THE 
TIME 
HALF 
OF THE 
TIME 
SOME 
OF THE 
TIME 
NONE 
OF THE 
TIME 
 
10 Windy conditions? 4 3 2 1 0 N/A 
11. Places or areas with low 
humidity? 
4 3 2 1 0 N/A 
12. Areas that are air 
conditioned? 
4 3 2 1 0 N/A 
  Sub Total score for answr 1 to 5  
 
SUM OF SCORE FOR ALL QUESTIONS ANSWERED  
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APPENDIX F: COLOUR PLATES 
 
Piture 1:  showing the Schirmer I test being done in patient 
 
 
 
Picture 2: showing Fluorescein strip, Lissamine green strip and Schirmer strip 
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Picture 3 :showing the fluorescein stain used in TBUT and OSS (cornea staining 
pattern) 
 
 
 
Picture 4 :showing Lissamine green staning pattern of conjunctiva 
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APPENDIX G: EXCEL DATA SHEET 
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